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Dear Reader,
Welcome to the neuro-oncology special issue of JHN Journal. The
research you’ll find in this issue highlights advancements we have made
to further advance the science of this difficult field. I’m also pleased to
report that our division, housed within the Vickie and Jack Farber
Institute for Neuroscience – Jefferson Health, has continued to make
great strides in our academic and clinical missions, as well.

Christopher J. Farrell, MD

Last year, we met with over 1,500 new patients and performed nearly
1,000 surgeries. In order to continue to care for these patients in the
most seamless, multidisciplinary way, we added a third oncologist to
our division. I’m proud to welcome Nina L. Martinez, MD, to our
division. Dr. Martinez, an alumna of Jefferson’s neurology residency,
rejoins us after completing a neuro-oncology fellowship at Memorial
Sloan Kettering Cancer Center and serving as an attending at Chicago’s
NorthShore University HealthSystem.
Our skull-base fellowship continues to offer trainees some of the
country’s most advanced training in the field. The graduates since our
last neuro-oncology special issue, published two years ago, have
achieved great success. Varun Khsettry, MD, joined the staff at
Cleveland Clinic and Alan Siu, MD, is pursuing a second fellowship at
Semmes Murphey Clinic, one of my alma maters. I’m confident our
current fellow, Hermes Garcia, MD, will achieve similar success after his
graduation this summer.
Finally, I wish to congratulate our division director and departmental
vice chair, David Andrews, MD, the inaugural Anthony Alfred Chiurco,
MD, Professor of Neurological Surgery. Dr. Chiurco, SKMC ’67, is a
practicing neurosurgeon in our area. A few years ago, our colleague
became a patient of Dr. Andrews when an emergency room visit
revealed he had a large brain tumor. His generous gift to our division
will continue to fuel our growth.
None of this would be possible without our ongoing partnership with
the NCI-designated Sidney Kimmel Cancer Center at Jefferson,
particularly our colleagues in radiation oncology. As you’ll find as you
read this issue, we are partners in research, education and clinical care.
Best regards,

Christopher J. Farrell, MD
Assistant Professor of Neurological Surgery
Vickie and Jack Farber Institute for Neuroscience
Member, Sidney Kimmel Cancer Center
Published by Jefferson Digital Commons, 2018

3

JHN Journal, Vol. 13 [2018], Iss. 1, Art. 7

BRAIN TUMOR TREATMENT AT JEFFERSON
William W. Keen, a Jefferson physician, performed America’s first successful brain tumor removal in 1888.
This rich tradition of innovation and excellence continues today in our multidisciplinary brain tumor
treatment program.

Our Physicians
The Vickie and Jack Farber Institute for Neuroscience, the home of our brain tumor program, consists of four
fellowship-trained neurosurgeons, two neuro-oncologists and one medical oncologist working together in
one center.
They’re joined by our colleagues in the Sidney Kimmel Cancer Center (SKCC) at Jefferson, one of 69 National
Cancer Institute (NCI)-designated clinical cancer centers for excellence in cancer care and research. We work
particularly closely with our colleagues in radiation oncology, a department that treats nearly 1,000 cancer
patients per year.

Our Resources
Our physicians have access to some of the most advanced technologies available for treating patients with
brain tumors. This includes both the Visualase® and Neuroblate® MRI-guided laser ablation technologies, a
GammaKnife™, a Varian True Beam STx Slim LINAC and advanced Brainlab® treatment planning software.
These resources are centered at Jefferson Hospital for Neuroscience (JHN), the Philadelphia area’s only
hospital dedicated to the treatment of neurological disorders. We’re proud to say JHN has achieved Magnet®
status, the highest distinction a healthcare organization can receive for excellence in nursing.
Physicians and basic science researchers from both the Farber Institute and SKCC are engaged in clinical and
translational research to improve outcomes for people living with brain tumors. Some of these research
projects include:
•A
 NTISENSE 102, an ongoing immunotherapy clinical trial for glioblastoma developed here
at Jefferson.
•C
 HECKMATE, a study that examines the efficacy of adding nivolumab to temozolomide and
radiosurgery for patients with MGMT-methylated glioblastoma.
•O
 ur area’s only CAP-accredited brain tumor lab, operated in conjunction with our colleagues
in the Department of Pathology.

Educational Opportunities
Thomas Jefferson University, home to the Sidney Kimmel Medical College, is proud to offer both undergraduate and graduate medical education. We offer:
•A
 third-year clerkship and a fourth-year sub-internship in neurological surgery.
We are pleased to accept visiting students into the fourth year rotation. For Jefferson
students, we also offer a fourth year research elective.
•A
 n ACGME-accredited residency program training three residents a year.
•M
 ultiple fellowships, including an SNS/CAST fellowship in neuro-oncologic surgery,
with a special emphasis in skull base surgery.

New Patient Appointments: 1-800-JEFF-NOW | Next day appointments usually available
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ABSTRACT
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival of less than 4 months
(m). This study evaluated the efficacy of fractionated stereotactic re-irradiation (FSRT)
for patients with HGG after progression on Bevacizumab.
Materials/Methods: Retrospective review was conducted of patients treated with
FSRT after progression on bevacizumab. A total of 36 patients were identified. FSRT
was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival
from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as
study endpoints. Univariate and multivariate analysis was performed.
Results: Among the 36 patients, 31 patients had recurrent glioblastoma, and 5 patients
had recurrent anaplastic astrocytoma. The median time from initial bevacizumab
treatment to FSRT was 8.5 m (range 2.3 – 32.0 m). The median plan target volume for
FSRT was 27.5 cc (range 1.95 – 165 cc). With a median follow up of 20.4 m, the overall
survival of the patients since initial diagnosis was also 24.9 m. The median overall
survival after initiation of bevacizumab was 13.4 months. The median overall survival
from FSRT was 4.8 m. FSRT treatment was well tolerated with no Grade >3 toxicity.
Conclusions: Favorable outcomes were observed in patients with recurrent HGG
who received salvage FSRT after bevacizumab failure. The treatment was well
tolerated. Prospective study is warranted to further evaluate the efficacy of salvage
FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed
bevacizumab treatment.
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INTRODUCTION
Malignant gliomas are the most common
brain tumors, with an estimated yearly
incidence of 3 per 100,000 people in the
United States.1 Despite multiple modalities for definitive therapy (which include
resection, radiation therapy (RT) and
chemotherapy), these lesions have an
unfortunately high rate of recurrence. 2
Therefore, even despite recent treatment advances in targeted therapies
for glioblastoma (GBM) and high grade
glioma (HGG) such as bevacizumab, the
long-term outcomes for these patients
remain poor.
In modern clinical practice, treatment
failure of recurrent HGGs largely represents failure of bevacizumab therapy.3
In addition to disease recurrence itself
driving poor outcomes, there is evidence
that these patients who fail bevacizumab
also harbor disease that is resistant to
other systemic therapies.4 Therefore,
treatment options for these recurrent
patients remain limited and their prognosis is dismal with a recent review of
sixteen studies reporting an overall
survival (OS) of under 4 months after
bevacizumab failure.4-6
Multiple modalities of radiotherapy have
been investigated for this population,
including stereotactic radiosurgery (SRS)
and brachytherapy. These interventions
have been shown to have modest utility,
but with the potential for significant
associated toxicity. In that context, fractionated stereotactic radiotherapy (FSRT)
is a promising treatment modality for the
treatment of these refractory HGGs. This
modality possesses the precise targeting
advantages of SRS but with the dosesparing radiobiologic properties of
fractionation to allow greater sparing
of surrounding critical structures, thus
limiting toxicity. 7,8 Taken together,
FSRT therefore possesses the potential
for decreased toxicity as compared to
SRS while still providing excellent local
control.9 The present study sought

6
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to evaluate the safety and efficacy of
FSRT in patients who failed therapy with
bevacizumab.

Table 1. Patient Demographic and Treatment Information. Descriptive data on our study cohort is
shown, encompassing demographic data, clinical information and treatment information.
Number of patients

MATERIALS AND METHODS
Patients
The Thomas Jefferson University institutional review board approved this
single-institution, retrospective study.
Patients who received FSRT salvage
after progression on bevacizumab were
included. A total of 36 patients were identified from 2006 to 2013. Patients who
received FSRT within 2 months of initiation
of bevacizumab were excluded. Patients
were followed with MRI scans and clinical
assessment, which were obtained 6 to 8
weeks after FSRT and at approximately
2-month intervals thereafter.

36

Gender
Male

17

Female

19

Median Age at FSRT salvage (range)

56 years (37-73)

Median KPS at FSRT salvage (range)

80 (50-100)

Histology at Recurrence
GBM

30

Anaplastic glioma

4 (3-4)

Other

2 (1-2)

Median Volume of Recurrence (range)

27.5 cc (1.95-165)

Median Radiation Dose (range)

35 Gy (30-37.5)

Median time from Bev to FSRT (range)

(2.4-32.1)

Treatment Planning
Treatment decisions were based on
consensus recommendations following
discussion in our institution’s multidisciplinary brain tumor board consisting of
radiologists, neurosurgeons, neuro-oncologists, neuropathologists and radiation
oncologists. Prior to 2004, treatment planning was conducted with the X-knife 3-D
planning system (Radionics, Burlington,
MA, USA), which delivered 6 MV photons
with a dedicated stereotactic 600SR linear
accelerator (Varian, Palo Alto, CA, USA).
From 2004 to 2013, treatment planning
was carried out with Brain Lab (Novalis)
using mMLC leaves with a leave thickness
of 3 mm and Exac Trac on board imaging.
All patients undergoing irradiation were
fitted with custom-made Brainlab (Munich,
Germany) thermal plastic masks for
immobilization. Treatment planning MRI
and computed tomography (CT) images
were obtained and fused. All patients had
thin cut (1-1.5 mm) fat suppressed coronal
post-contrast MRI. The gross tumor
volume (GTV) was defined on MRI using
the gadolinium enhanced T1 weighted
series, as peripherally enhancing tissue.
Surrounding edema was not purposely
included in the treatment volume. The
planning target volume was the GTV with
minimum margin (0-2 mm per the treating
physician). Critical normal structures, such
as optic nerves, chiasm, and brainstem
were also contoured. Treatment planning was carried out with Brain Lab Iplan
(Munich, Germany). The radiation planning used dynamic conformal arcs, IMRT

Published by Jefferson Digital Commons, 2018

(intensity modulated radiation therapy) or
hybrid-Arcs (Brainlab, Munich, Germany),
a combination of dynamic arcs with IMRT
beams. The patients were treated with
FSRT to a median PTV dose of 35 Gy
delivered in 3.5 Gy fractions.10 The dose
was reduced to 30 Gy in 3 Gy fractions
for large targets, and high critical normal
structure dose. The constraints for normal
critical structures include: brainstem max
dose <20 Gy; optic nerve max dose < 15
Gy, chiasm max dose < 15 Gy.

Statistical analysis
The primary end point of the study was
overall survival from initial diagnosis, as
well as survival from first recurrence and
re-irradiation (described in greater detail
under Statistical Analyses). Toxicity was
also graded using Radiation Therapy
Oncology Group (RTOG) criteria. Overall
survival was defined as the time from
initial diagnosis to the time of death. Date
of recurrence was defined as the date of
radiographic evidence of progression.
Survival from recurrence and from reirradiation were therefore defined as the
time from this radiologic evidence or
radiation therapy until death, respectively.
Kaplan–Meier curves were generated for
the overall survival endpoint. Cox proportional hazard modeling was used for
multivariate analysis with factors analyzed
in a step-wise fashion. All statistical analysis was performed using the STATA data
analysis and statistical software version
13.1 (STATA Corporation).

RESULTS
Patient Population and Treatment
Parameters
We identified 36 patients with either
anaplastic astrocytoma (5 patients) or
glioblastoma multiforme (GBM) (30
patients) who had clinical and radiographic evidence of tumor progression on
bevacizumab and received FSRT between
2006 and 2013 (Table 1). One patient
had gemistocytic astrocytoma. Patient
characteristics are listed in Table 1. There
were 17 males and 19 females. All patients
received initial surgery and were treated
with radiation and temozolomide. The
median age at recurrence was 57.1 years
(range 37-73). The median Karnofsky
Performance Status at recurrence was
80%. Following disease progression on
bevacizumab, the median target volume
treated with FSRT was 27.5 cc (range
1.95 – 165 cc). The median dose was
35 Gy (range, 30 Gy – 37.5 Gy).

Survival
Patients underwent routine surveillance
for a median follow up of 20.4 m after
initial diagnosis, with an overall survival
from initial diagnosis of 24.9 m. Upon
evidence of initial disease recurrence,
patients were promptly started on bevacizumab. The median overall survival
after initiation of bevacizumab was 13.4
months. The median time from initial
bevacizumab treatment to initiation of

JHN JOURNAL
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Table 2. Survival Statistics. Survival data accrued from the study cohort is shown, expressed as
OS from diagnosis, recurrence and from FSRT.
Median Overall Survival (Range)
From Diagnosis

24.9 months (11.4-94.2)

From First Recurrence

12.0 months (4.2-49.1)

From FSRT

4.8 months (0.5-23.4)

Overall Survival

Prior to FDA-approval of bevacizumab,
FSRT had been previously studied in the
setting of recurrent HGG, with generally
favorable results. Multiple studies have
shown FSRT to be efficacious, with OS in
these studies ranging from 5-11 months.
Moreover, these studies showed FSRT to
be very well tolerated, with a low rate of
grade 3 toxicities, radiation necrosis (RN)
and reoperation.10-12

Percent survival

100

50

0

0

20

40

60

80

100

Time (Months)

Figure 1. Kaplan-Meyer Overall Survival Curve.
Graph displays OS from the time diagnosis for patients who went on to fail bevacizumab
therapy and require FSRT in our study cohort.
salvage FSRT was 8.5 m (range 2.4 – 32 m),
and the median overall survival after FSRT
was 4.8 m. Data are presented in table form
(Table 2) as well as in the form of a KaplanMeyer survival curve (Figure 1).

p=0.04). Additionally, there was a trend
towards significance for re-resection
status associated with OS from FSRT (HR
1.87 p=0.17).

Multivariate Analysis

No patients demonstrated clinically
significant acute morbidity, with no grade
III or higher toxicity observed. All patients
were able to complete the prescribed
radiation course without interruption.
There were no observed hospitalizations
or surgeries for early acute or delayed
toxicity in the study population.

Multivariate analysis was performed to
investigate whether different variables
in our study population influenced OS
from recurrence or from FSRT therapy
(Table 3). These included age at recurrence, KPS score, volume of recurrence,
histology (AA vs GBM) or re-resection
status. Importantly, out of all of these
variables, only re-resection demonstrated
a statistically significant association with
overall survival from recurrence (HR 2.59;
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in patients with high-grade gliomas,
treatment failure and disease progression while on bevacizumab remain as
an unfortunate reality in managing these
patients. Therefore, overall prognosis
remains quite poor. Despite this clinical
need, there remains a paucity of literature
regarding the management of patients
who fail bevacizumab. In that context,
the present study investigated FSRT as a
potential treatment modality to address
this problem.

Toxicity

DISCUSSION
Despite recent advances such as bevacizumab that have extended overall survival

Of note, one study (Lederman et al.)
observed significantly more toxicity and
reoperation (11 of 88 patients) than the
others. This toxicity outlier can perhaps
be explained by the use of a different
dosing regimen (24 Gy in 4 fractions in
Lederman et al. versus 30-35 Gy in 6-10
fractions in the other studies).13 In a head
to head trial, Patel et al. compared stereotactic radiosurgery (SRS) with FSRT and
showed comparable overall survival and
radiographic tumor response between
the two modalities, with a trend towards
fewer events of radiation necrosis (RN) in
the FSRT cohort.14
The data on FSRT treatment following
bevacizumab failure is much more
limited. In a retrospective study, Torcuator et al. looked at two cohorts of
patients who failed bevacizumab: one
that received either FSRT or SRS and one
that received no FSRT/SRS. They demonstrated an increased overall survival in
patients receiving FSRT/SRS (7.2 vs 3.3
months in untreated patients). Another
study that is published only in abstract
form by Nehaw et al. similarly looked at
RT (including 6 patients who received
FSRT) versus non-RT regimens following
bevacizumab failure and showed statistically significant increased survival in the
radiation group (8.8 vs. 5.4 months for
untreated). Despite this small body of
literature, neither of these studies investigated FSRT alone after bevacizumab
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Table 3. Multivariate Analysis. Multivariate analysis is shown for the study cohort. Variables
were tested for association with OS from Recurrence as well as OS From FSRT. Data are
expressed as Hazard Ratios (HR) and p-value. P-value of <0.05 was considered significant.
OS from Recurrence Multivariate
Age at Recurrence

HR=0.99; p=0.67

KPS <=80

HR=1.27; p=0.61

Volume of recurrence >50cc

HR=1.09; p=0.32

Re-resection yes vs no

HR=2.59; p=0.04

Histology AA vs GBM

HR=0.99; p=0.99

OS from FSRT Multivariate
Age at Recurrence

HR=1.01; p=0.70

KPS <=80

HR=0.73; p=0.53

Volume of recurrence

>50cc HR=1.02; p=0.83

Re-resection yes vs no

HR=1.87; p=0.17

Histology AA vs GBM

HR=1.72; p=0.46

failure, nor did they report on safety or
toxicity of these approaches.
In that context, the present study
represents one of the first studies
to specifically investigate the role of
FSRT in the context of bevacizumab
failure. Indeed, our work builds off of
previous work by both our group and
others showing comparable benefit and
improved safety in FSRT regimens for
HGGs as compared to SRS for treatment
of HGG in other contexts.10,11,13 Specifically, the present study demonstrates
the feasibility, efficacy and tolerability
of such an approach in patients who fail
bevacizumab.
One limitation of our study is the lack of
a control cohort for comparison in terms
of outcomes to put our overall survival
into context. Historically, patients who
fail bevacizumab have been shown in a
recent review of sixteen studies to have
an overall survival of 3.8 months.4-6
Thus, our observed overall survival
compares favorably to, and indeed
exceeds that mark. Taken in the context
of the aforementioned studies which
show benefit of RT vs. no RT in bevacizumab failure, and also that FSRT and SRS
provide similar OS in recurrent gliomas
before bevacizumab treatment, our data
are consistent with these previous studies
and moreover suggest a role for FSRT in
the management of patients who fail

Published by Jefferson Digital Commons, 2018

bevacizumab. Despite our findings, it is
worth noting that one limitation of our
study is the potential bias of our dataset
in that it only includes patients who are
amenable to therapy with FSRT. Therefore it is difficult to directly compare our
survival data to the existing literature,
given that the literature includes all
patients, whether or not they are eligible
for FSRT. Further head-to-head studies
will be needed to evaluate FSRT versus
other modalities to definitively establish
a role and identify populations that would
most benefit.
Notably, our multivariate analysis yielded
only one variable that was associated with overall survival: re-resection
status. Indeed, there is controversy in
the literature regarding the prognostic
value of re-resection in patients with
recurrent HGG,2 but our data suggest
that re-resection is actually deleterious
in terms of survival outcomes. However,
given the retrospective nature of the
current study, it is difficult to draw strong
conclusions from these data, as re-resection status itself may be confounding by
representing underlying patient characteristics that lead to poorer prognosis.
Future studies will be needed to identify
patient populations who will most benefit
from an FSRT regimen.
Other limits to our study include a small
patient cohort (36) as well as those shortcomings inherent to all retrospective

studies including selection bias and
potential treatment differences in a
non-randomized study. Despite these
potential drawbacks, this study represents, to our knowledge, the largest
literature cohort of FSRT patients in the
context of bevacizumab failure. Moreover, the dire prognosis of these patients
and the paucity of data regarding their
management underscores the relevance
of the present study, and suggests the
need for future prospective randomized
trials to improve survival and positively
impact the lives of patients with HGG.

CONCLUSIONS
Favorable outcomes were observed using
FSRT to treat patients with recurrent HGG
and the treatment was well tolerated.
Prospective study is warranted to further
evaluate the efficacy of salvage FSRT for
patients with recurrent HGG after bevacizumab failure.
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ABSTRACT
Background: Extending a previous Phase I study, we report the results of a second
Phase I autologous tumor cell vaccination trial for patients with recurrent glioblastomas
(IND 14379-101, NCT01550523).
Methods: Following surgery, subjects were treated by 24 hour implantation in the
rectus sheath of ten biodiffusion chambers containing irradiated autologous tumor cells
and IGF-1R AS ODN with the objective of stimulating tumor immunity. Patients were
monitored for safety, clinical and radiographic as well as immune responses.
Results: There were no Grade 3 toxicities related to protocol treatment and overall
median survival from initial diagnosis was 91.4 weeks. Two protocol survival cohorts
with median survivals of 48.2 and 10 weeks were identified and predicted by our
pre-treatment assessments of immune function, corroborated by post-vaccination
pro-inflammatory cytokine profiles. Longer survival subjects had imaging findings
including transient elevations in cerebral blood volume (rCBV) and sustained elevations
of apparent diffusion coefficient (ADC) interpreted as transient hyperemia and cell loss.
Conclusions: The vaccine paradigm was well-tolerated with a favorable median
survival. Our data support this as a novel treatment paradigm that promotes anti-tumor
immunity.

KEYWORDS
Decompressive Hemicraniectomy, Intracerebral Hemorrhage, Malignant MCA Stroke,
Traumatic Brain Injury, Aneurysmal Subarachnoid Hemorrhage, Intracranial Pressure,
Herniation

INTRODUCTION
WHO Grade IV astrocytoma (glioblastoma) is a uniformly fatal primary intracranial malignancy with a median survival of 14 months.1 We conducted an earlier pilot Phase I vaccine
trial in patients with high grade astrocytomas2 and designed a replacement Phase 1 trial
with optimized reagents, expanded radiographic response criteria, and new exploratory
objectives.

METHODS
Study Site and Patients
The study was conducted at Thomas Jefferson University and reached target accrual
of 12 patients in 14 months. Criteria for enrollment included age > 18, a Karnofsky
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performance score of 60 or better, and
no co-morbidities that would preclude
elective surgical re-resection. Twelve
patients were enrolled for treatment after
failure from standard therapy.1 A summary
of enrolled patients, and all available pertinent data is included in Table 1.

Study Design and Objectives
As before, the combination product
consisted of autologous tumor cells
removed at surgery then treated overnight with the IGF-1R AS ODN (4mg/ml)
prior to being added to semi-permeable
chambers and irradiated. 2 Enhancements to the vaccine product included
use of an 18-mer IGF-1R AS ODN with
the sequence 5’-TCCTCCGGAGCCAGACTT-3’, two frameshifts upstream
from the previous sequence; and, based
on data showing that the AS ODN has
immunomodulatory properties,3,4 addition of 2 mg of exogenous antisense to
the chambers (C-v). The protocol was
also amended to include an eleventh
control chamber containing PBS (C-p).
Study objectives included assessment
of safety and radiographic responses as
well as exploratory objectives looking at
immune function and response.

Radiological Assessments
Serial imaging assessments were
performed on Philips 1.5T and 3T MRIs
and GE 1.5 T MRIs. Routine anatomic MRI
features were evaluated as well as physiologic measurements including dynamic
susceptibility weighted (DSC) MR perfusion and 15-direction diffusion tensor
imaging (DTI) were also utilized.

Immunological Assessments
Plasma leukopheresis was performed
one week before surgery for baseline
assessment of immune function. Blood
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Table 1. Summary of Patients Enrolled.
Subject

Age

KPS

Interval between
surgeries (weeks)

# chambers
implanted

Original lymphocyte
count (cells/mm2)

Lymphocyte count
at enrollment
(cells/mm2)

Previous
treatments

IDH-1 mutation/
MGMT methylation

TJ01

39

70

177

10

N/A

400

S,RT + TMZ, Bev

-/

TJ02

57

80

90

9

N/A

1570

S,RT + TMZ

-/methylated

TJ03

75

70

32

7

700

300

S,RT + TMZ

-/

TJ06/R1

66

80

54

8

2000

1300

S,RT + TMZ

-/

TJ07

43

80

215

10

500

430

S, RT + TMZ,
Bev; RTOG 0525

+/

TJ08

55

80

52

8

1000

500

S,RT + TMZ

-/

TJ09

57

80

61

7

1400

300

S, RT + TMZ,
RTOG 0929

-/unmethylated

TJ10

47

60

376

7

N/A

1800

S, RT + TMZ, Bev

-/methylated

TJ11

39

70

32

11*

2400

200

S, RT + TMZ

-/

TJ12

60

80

74

7

1100

600

S, RT + TMZ,
Panobinostat

-/

TJ13

64

80

182

11

N/A

2100

S, RT + TMZ

-/

TJ14/R

77

90

30

7/11

1800

1100

S, RT + TMZ

-/unmethylated

1

Compassionate retreatment; *Protocol amendment to include control chamber filled with phosphate buffered saline; S: surgery; RT: radiation therapy;
TMZ: temozolamide chemotherapy; Bev: bevacizumab chemotherapy; IDH-1: isocitrate dehydrogenase-1

was obtained post-operatively on days
7, 14, 28, 42, 56, and every 3 months
after vaccination. Sera and cell fractions
were separated by centrifugation and
cells were treated with red blood cell
lysis buffer and white blood cells either
quantified by flow cytometry or stored
in DMSO at -80°C. Serum samples were
also stored at -80°C. Flow cytometry
was performed as previously described5
using an EasyCyte 8HT (Millipore) and
fluorescently-conjugated mAb specific
for human CD4, CD8,CD11b, CD14,
CD16, CD20, CD45, CD56, CD80, CD83,
and CD 86 (all from BD Biosciences), and
CD163 (R&D Systems). Post- collection
analysis was performed with FlowJo
software (Tree Star Inc, Ashland, OR).
Serum cytokine factors were quantified
using Luminex bead arrays (human cytokine/chemokine panels I, II, and III from
Millipore and HCMBMAG/ MILLIPLEX
Mag Cancer multiplex assay (emdmillipore.com). This included 6 serum markers
for glioma related to stem cell function
including DKK-1, NSE, Osteonectin,
Periostin, YKL-40, and TWEAK. T-cell
stimulation was performed with phorbol

8

https://jdc.jefferson.edu/jhnj/vol13/iss1/7
DOI: https://doi.org/10.29046/JHNJ.013.1

JHN JOURNAL

12-myristate,13 acetate (PMA) and ionomycin as previously described.6 PBMC
from glioblastoma patients and normal
donors were cultured for 24 hours at 37°C
and 5% CO2 in AIMV media containing
10% fetal bovine serum (Gibco). Nonadherent lymphocytes were transferred
to new plates in order to eliminate
non-specific effects of contaminating
monocytes. Lymphocyte cultures were
stimulated with phorbol 12-myristate
13-acetate (PMA, 100 ng/ml) and ionomycin (0.1 mM, both from Sigma-Aldrich)
for 18 hours. BD Golgiplug™ (1:1000,
Brefeldin A, BD Bioscience) was added
during the last 6 hours of culture to
permit cytokine accumulation.
Tumor tissue sections were assessed
by immunohistochemistry or immunofluorescence, adapting the method of
Emoto7, for GFAP, IGF-1R, CD163, CD14,
CD3, CD4, and CD8. Immunopositive
cells were counted quantitatively with
Aperio or qualitatively by an experienced
neuropathologist (LEK) using an ordinal
scale from 0 (no staining) to 6 (strong
diffuse staining) with staining intensity

rated as low, moderate and strong and
staining patterns described as focal or
diffuse.
Cytokine/chemokine levels in tumor cell
supernatant were analyzed by Luminex
kits as designated above. Membranes
from paired vaccine and control chambers were embedded in paraffin for
standard immunohistopathologic examination. Post-mortem autopsy was limited
to examination of the brain and findings
were compared to archival paraffin
blocks of previously treated or untreated
glioblastomas diagnosed at autopsy.

Statistical Analysis
The level of statistical significance
between quantitative measures in
different samples was determined by a
two-tailed unpaired t-test or matched
pairs t-test with p < .05. Survival analysis
was performed by Kaplan-Meier analysis
and significance established by log
rank comparisons. All statistical analysis
including mixture discriminant analysis
was performed with JMP v. 11 software
(SAS, North Carolina).
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Figure 1. Survival Metrics.
A. Overall survival of patients in trial; B. protocol survival with two survival cohorts; Nine patients died of disease progression while one died
of intracerebral hemorrhage and two of sepsis. Overall protocol survival was 48.2 weeks and 9.2 weeks, respectively for longer (N = 4) and
short (N = 8) survival cohorts (log-rank = .014). C. Excluding one outlier and three non-disease-related deaths linear regression revealed high
correlation between protocol survival and lymphocyte count at enrollment (R2 = .8, p = .0028).

RESULTS
Safety Assessment and Clinical
Course
Only one SAE was related to the protocol
(femoral vein thrombosis after leukopheresis). Nine patients succumbed to
tumor progression while three patients
died from other causes. Five autopsies
were performed.
Median overall survival from initial diagnosis was 91.4 weeks which compared
favorably to other recurrent glioma
immunotherapy trials.8-13 Two significantly different protocol survival cohorts
of 48.2 and 10 weeks were identified
as longer and short survival cohorts,
respectively (Figure 1A&B). Excluding
one outlier (TJ03), we documented a
significant correlation between protocol
survival and degree of lymphopenia at
enrollment (Figure 1C). Comparison of
CBC values at initial diagnosis and at
protocol enrollment indicated that the
mean lymphocyte count had dropped
significantly (65%) after standard therapy
(N=8, p = .012, paired t-test).

Radiographic Responses
Routine MRI features were assessed
as previously described.2 In the longer
survivors we noted diminished size
of enhancement and FLAIR envelope

Published by Jefferson Digital Commons, 2018

at the primary tumor site and slower
progression. Examples of anatomic
responses in both cohorts is included
noted in Figure 2A&B. Physiologic MRI
measurements augmented these anatomic
observations for both cohorts is featured
in Figure 2C&D. Sequential DSC MR perfusion was performed in 7 patients, including
3 longer-term survivors (TJ03, TJ06, and
TJ09) who had a paradoxical increase in
rCBV while improving clinically; however,
this effect was transient and there was
a more sustained decrease in rCBV.
Sequential 15 directions DTI data included
two long-term survivors (TJ03 and TJ06)
who showed ADC values increasing in the
affected hemisphere, reflecting loss of
tumor cellularity associated with disease
regression.

Immunologic Response
Assessments after Vaccination by
Survival Cohort
Levels of 24 of the 78 cytokines/chemokines assessed were significantly higher
in serum from the longer survival cohort
compared to the short cohort. A spike in
serum CCL2 occurred after surgery but
was absent at re-operation in two patients.
CCL2 levels remained significantly higher
throughout the post-operative period in
the short survival cohort. These postoperative spikes were highly correlated
with TNF-a spikes. (data not shown).

Actual CD4 and CD8 T cell counts as well
as DC counts were significantly higher in
the longer cohort compared to the short
cohort. There was a significant correlation
between CD4 and DC cells and between
CD4 and CXCL12 only in the longer
cohort. Coordinated changes between
circulating levels of T cells, monocytes,
and pro-inflammatory chemokines/cytokines after vaccination were seen in three
of four longer cohort subjects.
As a distinguishing feature differentiating
the cohorts, peripheral blood cells from
the longer survival subjects manifested
significantly higher Th-1 cytokine production including IFN-g after stimulation with
PMA and ionomycin from PBMC obtained
on day 14.
Levels of circulating lymphocytes were
significantly decreased (p<0.0001) in all
GBM patients when compared to normal
subject samples (Figure 1A, left panel) and
the medians of both patient populations
fell outside of the normal range (Figure
1A, gray lines). Patients in this same cohort
exhibited significantly higher levels of
monocytes (Figure 1A, right panel, p<0.05),
but the medians of these cell populations
fell within normal range.
The mere presence of a given cell
subset is not enough to ensure proper
immune function. The cell must also be
able to respond to stimuli and produce
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A

B

C

D

Figure 2. Radiographic responses with associated physiologic measurements and cytokine profiles.
A. Examples of short survival cohort. TJ11: A-D; TJ10: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; G: T1-gadoliniumenhanced coronal image; C: pre-operative axial FLAIR image. B,D,F,H: respective 3 month post-operative images. B. Examples of longer
survival cohort. TJ06: A-D: TJ09: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; C,F: pre-operative axial FLAIR images.
B,D,F,H: respective 3 month post-operative images. C. Relationship between relative cerebral blood volume in tumor v. apparent diffusion
coefficient in short survival cohort. D. Relationship between relative cerebral blood volume in tumor v. apparent diffusion coefficient in
longer survival cohort; there is a high correlation between the ADC and rCBV (R2 = .96, p = .0005).

appropriate immune modulators.
T-helper type 1 immunity is considered to be the appropriate anti-tumor
immune response. Cultures of nonadherent lymphocytes were stimulated
nonspecifically with phorbol 12-myristate
13-acetate (PMA) and ionomycin overnight in order to stimulate the production
of IFN-g, the prototypical Th1 cytokine
which was detected by intracellular
cytokine flow cytometry. Viable, CD3+
T cell-specific gates were established
(Figure 1B) and the median fluorescence
intensity (MFI) of IFN-g+ T cells was
normalized to T cells that did not produce
cytokine (IFN-g+ T cells). PMA/ionomycin
stimulation of normal T cells resulted in a
26-fold increase in the IFN-g MFI (Figure
1B, right panel). T cells enriched from
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patients with primary and recurrent GBM
produced significantly less IFN-g when
compared to normal controls (p< 0.01),
but there was no difference between
GBM patient cohorts (Figure 1B, right
panel).
Moreover, while a difference in the
quantity of IFN-g produced by the T cells
was observed, there was no difference in
the frequency of IFN-g+ T cells between
these two cohorts (data not shown). In
order to assess the relationship between
lymphocyte numbers and immune functional capacity, we performed linear
regression analyses. Lower levels of
circulating lymphocytes are associated
with a statistically significant (R2=0.508,
p=0.0093) decrease in IFN-g production
following PMA/ionomycin stimulation

(Figure 1C, left panel). Furthermore,
recursive partitioning analyses identified
two different populations (R2=0.547) of
recurrent GBM patients enrolled in our
clinical trial (Figure 1C, right panel).
Reanalyzing these data focusing on
single parameters based on the functional immune capacity confirmed the
highly significant differences identified
by recursive partitioning (Supplementary
Figure 1). Patients with higher immune
function possessed 3-fold higher levels of
lymphocytes (p<0.0001) and half as many
monocytes (p<0.005) when compared to
the lower functioning group (Supplementary Figure 1). In addition to higher levels
of lymphocytes, the T cells from patients
with higher immune function produced
twice as much IFN-g following stimulation
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A. Lymphocyte and monocyte frequencies are expressed as a percentage of white blood cells as determined by clinical blood counts
performed by Thomas Jefferson University Hospital. Frequencies in trial patients are compared to primary glioblastoma patients and
normal blood donors. Scatter dot plots indicate the mean frequency and standard deviation. Statistical significance of differences between
tumor patients and normal blood donors were assessed by ANOVA followed by Dunnett’s post-test (****p<0.0001 and *p<0.05). Gray
lines represent the upper and lower range of normal values. GBM signifies newly diagnosed patients; GBMr signifies recurrent glioblastoma
patients. B. Non-adherent peripheral blood mononuclear cells were stimulated with PMA/ionomycin and cytokine production was assessed
by intracellular flow cytometry. Live cell gates were established in forward- and side-scatter plots (left panel). Quadrant gates were used
to assess IFN-g production in CD3+ T lymphocytes (middle panel). Numbers indicate the frequency of cells in a given quadrant. Median
fluorescence intensity of IFN-g +CD3+ cells was normalized to IFN-g -CD3+ cells and is presented as a ratio in scatter dot plots (right panel).
Statistical significance of the difference between tumor patients and normal blood donors was assessed by ANOVA followed by Dunnett’s
post-test (***p<0.0005). C. Left panel: Recursive partitioning analysis separated the trial patients into groups with higher and lower
immune functional capacity (R2=0.547). Right panel pair: Linear regression analysis of IFNg production versus peripheral blood lymphocyte
frequency revealed a significant association of these variables only in the longer survival cohort with a positive correlation (R2=0.83).
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with PMA/ionomycin (Supplementary
Figure 1, p<0.01). Subsequent analyses
will focus on patients with higher/lower
functional immune capacity. Analysis of
hospital-acquired blood cell counts fail
to take in to consideration immune cell
subsets. We performed flow cytometry
phenotyping in order to further characterize the white blood cells. Frequencies
of CD20+ B cells were significantly
decreased in those patients with lower
cohort (p<0.005) and fell outside of the
normal average (Figure 2). CD4+ T cells
in both cohorts were significantly lower
than the normal average, while CD14+
monocytes were significantly increased
compared to normal averages (Figure 2) in
both partitioned cohorts. CD8+ T cells in
both cohorts were similar to normal averages (Figure 2). There was no difference
between the lower and higher cohorts
with respect to CD4+ or CD8+ T cell, or
CD14+ monocyte frequencies (Figure 2).

DISCUSSION
Like its predecessor, the revised
autologous cell/chamber-based GBM
vaccination trial did not raise any significant safety concerns. We recognized,
however, that an immunotherapy trial
for recurrent GBM faces incumbent challenges. Patients emerging from standard
therapy for GBM often have severe leukopenia,14 which was also documented in
the current trial. It was therefore not
surprising that we could not document T cell infiltrates in the TME after
treatment. Surgery itself enhances host
immune mechanisms favoring tumor
growth through the attraction of M2
macrophages to the tumor environment
postoperatively15,16 suggested by the CCL2
serum spike provoked by craniotomy.
Other than this post-operative serum
spike, the highest levels of CCL2 expression were found in the tumor supernatants
during vaccine preparation supporting
well-documented observations that CCL2
is produced from cells in the TME.17,18 The
lack of a CCL2 peak after re-vaccination in
two patients suggested loss of these cells
after the first vaccination.
We identified two significantly different
survival cohorts with different responses
to this vaccine paradigm allowing us to
explore the nature of potentially therapeutic immune mechanisms. Serum from
the longer cohort subjects contained
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higher levels of tumor-specific antibody
isotypes and cytokines/chemokines
commonly associated with Th1 immunity including IgG1, IgG3, IL12, CXCL10,
CXCL12, CCL7, CCL19, and CCL21 not
seen in the short cohort.
The short survival cohort had longer
overall survival perhaps in part due to
MGMT methylation and better responses
to temozolamide in three patients.
However the treatment-induced lymphopenia and the lower CD4:CD8 ratio could
perhaps also be ascribed to temozolamide. Also, elevated serum CCL2 levels
found in the short cohort have been
associated with the mesenchymal gene
expression profile19 and a poor prognosis20 in glioma patients.
Cytokine production is a hallmark feature
of immune function in lymphocytes. We
used phorbol ester-mediated, non-specific
stimulation of patient lymphocytes in order
to stimulate maximal cytokine output as a
surrogate indicator of immune function.
IFN-g is the classical Th1 cytokine and the
logical choice for assessing immune fitness
of T lymphocytes in our GBM patients.
The amount of IFN-g production by T
cells following overnight stimulation was
approximately half the amount produced
by normal donor cells treated similarly.
IFN-g production and lymphocyte counts
were strongly associated and predictively
identified patients with different levels of
immune fitness that fell into either the
longer or short survival cohort. Lymphocytes from patients with higher functional
immune capacity were more frequent
and produced higher levels of IFN-g that
approached levels to those produced by
normal lymphocytes stimulated under
similar conditions. In contrast, T cells from
trial patients in the lower immune function cohort were less in number (50%) and
unable to respond to PMA stimulation.
The implanted chambers have inherent
adjuvanticity. We have confirmed that the
antisense sequence, its CpG motif, and
the direct mixture with glioma cells in situ
effectively initiate anti-tumor immunity3
also noted by others.21,22 The CpG motif
specifically interacts with TLR94 causing
plasmacytoid DC activation, measured
by CD80 and CD86 expression.5 The
elevated CD4:CD8 ratio after vaccination
in the longer survival cohort could reflect
local TLR9 DC activation and CD4 T cell
stimulation.

Evolution of resistance to treatments in
gliomas has now been associated with
activation of the IGF-1R signaling axis
and IGF-1R inhibition through a small
molecule inhibitor overcomes this resistance with improved outcomes.23 We
are currently exploring the impact of the
IGF-1 bioregulatory system in recurrent
gliomas and the impact of the IGF-1R AS
ODN in this vaccination paradigm.
Differences in the radiographic observations between the longer and short
survival patient cohorts provide further
support for the concept that the vaccination paradigm may have an impact on
the glioma TME. Higher rCBV values are
typically associated with tumor progression,24 and MR perfusion had only
transient increases in the longer cohort,
a finding not previously described. ADC
measurements differentiated tumor
progression (lower values) from what we
interpreted as cell loss (higher values).25
In summary, we have established the
safety profile of an improved combination glioma vaccine product and have
documented alterations in immune
parameters associated with clinical and
radiographic improvements. Despite
immune compromise, we documented
favorable immune responses associated
with tumor regression and longer survival
after treatment. To be most effective,
however, a replacement trial should
include screens for immune compromise
and means by which immune function
could be restored prior to vaccination.

Study Oversight
The physician sponsor (DWA) was
primarily responsible for the design
and funding of the study. All authors
participated in the conduct of the study,
analysis of the data and the reporting of
the results. After IRB approval, this study
was overseen by an independent data
safety and monitoring board appointed
by the Sidney Kimmel Cancer Center at
Thomas Jefferson University.
DWA and DCH have financial interests in
the Imvax Corporation related to this work.
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ABSTRACT
Purpose: We performed a phase I study to determine the maximum tolerable dose
(MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain
radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.
Methods: Based on intracranial (IC) disease burden, patients were treated with WBRT
(Arm A) or SRS (Arm B). Ipilimumab starting dose was 3 mg/kg (every 3 weeks, starting
on day 3 of WBRT or 2 days after SRS). Ipilimumab was escalated to 10 mg/kg using a
two-stage, 3+3 design. The primary endpoint was to determine the MTD of ipilimumab
combined with radiotherapy. Secondary endpoints were overall survival (OS), IC and
extracranial (EC) control, progression free survival (PFS), and toxicity. This trial is registered with ClinicalTrials.gov, number NCT01703507.
Results: Characteristics of the 16 patients enrolled between 2011 and 2014 were: mean
age, 60; median BM, 2 (1 to >10); number with EC disease, 13 (81%). Treatment included
WBRT (n=5), SRS (n=11), ipilimumab 3mg/kg (n=7), 10 mg/kg (n=9). Median follow-up
was 8 months (Arm A) and 10.5 months (Arm B). There were 21 grade 1-2 neurotoxic effects with no dose-limiting toxicities (DLTs). One patient experienced grade 3
neurotoxicity prior to ipilimumab administration. Ten additional grade 3 toxicities were
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reported with gastrointestinal (n=5, 31%)
as the most common. There were no
grade 4/5 toxicities. Median PFS and OS,
respectively, in Arm A were 2.5 months
and 8 months, and in Arm B were 2.1
months and not reached.
Conclusion: Concurrent ipilimumab 10
mg/kg with SRS is safe. The WBRT arm
was closed early due to slow accrual, but
demonstrated safety with ipilimumab 3
mg/kg. No patient experienced DLT. Larger
studies with ipilimumab 10 mg/kg and SRS
are warranted.

INTRODUCTION
Brain metastases (BM) occur in more
than half of patients with advanced
melanoma, and central nervous system
disease burden often contributes to their
death.1,2 The historic median survival
of patients with BM from melanoma is
4.7 months.3 Traditional BM treatment
options includes surgery, whole brain
radiation therapy (WBRT), and stereotactic radiosurgery (SRS), and can prevent
neurological decline and may also
improve overall (OS).4-7 There has been
increasing interest in radiotherapy (RT)
combined with immunotherapy (IT) with
growing evidence supporting a potential
synergistic effect. It remains unclear the
role that this synergism has on toxicity.8
Activated T-cells and antibodies targeting
tumor-associated antigens (TAAs)
detected in blood from cancer patients
supports an active role for an anti-tumor
immune response.9 T-cell infiltrates in
melanoma have prognostic significance,
and when identified within nodal metastases, predict benefit in patients treated
with neoadjuvant interferon-α-2b.10-13
Cytotoxic T-lymphocyte-associated antigen
4 (CTLA-4), is a negative regulator of
T-cell-mediated anti-tumor immune
responses and therefore represents a
critical checkpoint, controlling both
response duration and intensity.14-16 Ipilimumab (MDX-010, Bristol-Myers Squibb)
is a fully human monoclonal antibody
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Figure 1. Treatment Schedule

directed against the CTLA-4 receptor and
is FDA approved for patients with unresectable or metastatic melanoma.17,18,19
One of the larger studies to investigate
ipilimumab evaluated 127 patients and
demonstrated an OS benefit (93 v. 42
weeks, P=0.0028) for patients who
received concomitant IT and RT.20
Early in vitro studies showing a broad
shoulder in the cell survival curves and a
high repair rate in melanoma cells have
inferred better tumor response with
higher radiation doses.21,22 Moreover, SRS
delivery in close proximity to IT yields the
possibility of increased immunomodulation which has been hypothesized to
have an effect on distant control. This
so-called “abscopal effect” is rare and
intriguing, although specific mechanisms
are currently incompletely understood.23,24 In addition to the potential
immunogenic advantages, concomitant
treatment also limits delays in subsequent
therapy.
To the best of our knowledge, we report
the first prospective phase I study evaluating concurrent ipilimumab with SRS or
WBRT for patients with melanoma BM,
assessing the safety and tolerability of
concomitant therapy as well as intracranial (IC) and extracranial (EC) control,
progression-free survival (PFS), and OS.

MATERIALS AND METHODS
Study Design and Participants
This IRB-approved, open-label, phase I,

Published by Jefferson Digital Commons, 2018

clinical trial was performed between
October 2012 and August 2014, at
Thomas Jefferson University and Ohio
State University. All patients were over 18
years old, Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1,
with normal hepatic and renal function
and with histologic and radiographic
confirmation of diagnosis. Blood count
requirements were as follows: absolute
neutrophil count ≥ 1000/µL, hemoglobin
≥ 9g/dL, platelets ≥ 75,000/µL. Patients
were excluded if they had a history of
chronic infection (HIV or Hepatitis),
autoimmune condition, abnormal
thyroid function, or leptomeningeal
carcinomatosis.

Radiotherapy
Patients were enrolled onto one of two
arms depending on their IC disease
burden. Arm A (WBRT) included patients
with 5 or more BM, any lesion >4 cm
maximal diameter, or 1 completely
resected BM with postoperative cavity >4
cm. Arm B (SRS) included patients with
fewer than 5 BM (all ≤4 cm in diameter)
or a single postoperative cavity <4 cm.
Within each arm, RT dose was predetermined. WBRT dose was 30 Gy in 10
fractions. Ipilimumab was administered
on day 3 of RT in Arm A. Arm B patients
received SRS according to the maximum
diameter of the BM or resection cavity
according to dose prescriptions in RTOG
90-05.25 Ipilimumab was administered
2 days following SRS in Arm B (Figure 1).

Dose-Escalation Scheme
Ipilimumab was administered intravenously over 90 minutes once every 3
weeks for 4 total doses and was doseescalated independently in each arm
with no intra-patient escalation. The FDA
approved dose of 3 mg/kg was the starting
dose. Rationale for ipilimumab dose escalation to 10mg/kg was based on findings
from the randomized, double-blind,
phase 2 dose-ranging study of ipilimumab monotherapy demonstrating the
best overall response rate in the 10 mg/
kg group (11.1%, 95% CI 4.9-10.7) versus
the 3 mg/kg group (4.2%, 95% CI 0.9-11.7),
suggesting further investigation of this
higher dose.26 Following the initial 4 treatments, maintenance dosing was offered
to patients without unacceptable toxicity
(refractory grade > 3 immune-related
adverse events [irAEs]) at the same dose
level given every 12 weeks until disease
progression, toxicity requiring discontinuation, or consent withdrawal.

Dose-Limiting Toxicity
Adverse events (AEs) were recorded with
the Common Terminology Criteria for
Adverse Events version 4.0 (CTCAE v.4).
Dose-limiting toxicity (DLT) was defined
as any grade 3 or higher treatment related
toxicity occurring within 30 days of
completing RT. Any neurological toxicity
of grade 3, 4, or 5 was considered doselimiting (except symptoms present prior to
study enrollment or expected sequelae of
surgery or SRS). All patients were followed
for AEs for 4 weeks following the last dose
of ipilimumab. Intratumoral hemorrhage
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26 patients screened

17 deemed eligible
and consented

9 screen failures

Role of the Funding Source

1 patient never
recieved study terapy
due to deteriorating health

16 assigned
treatment & analyzed

Arm A, WRBT
n=5

Arm A, WRBT
n=5

lpilimumab
3 mg/kg

lpilimumab
10 mg/kg

lpilimumab
3 mg/kg

lpilimumab
10 mg/kg

4 in analysis
3 died; 1 alive

1 in analysis
1 alive

3 in analysis
1 died; 2 alive

8 in analysis
21 died; 6 alive

Figure 2. Consort Diagram

was defined as new or worsening signs
of bleeding within the irradiated tumor or
cavity volume.

Assessment of Efficacy
Contrast-enhanced MRI of the brain was
performed at week 7 and then every 2
months for 1 year, then every 3 months.
All MRIs were interpreted using Response
Evaluation Criteria In Solid Tumors
(RECIST, version 1.1)27 and immunerelated response criteria (irRC).28 Overall
response using irRC was classified as
immune-related complete response
(irCR), partial response (irPR), stable
disease (irSD), or progressive disease
(irPD) based on the predefined combination of parameters.28 For evaluation of
EC disease, CT of the chest, abdomen,
and pelvis was performed at week 7 and
13 following enrollment, and every 3
months subsequently.

Statistical Methodology
A two-stage 3+3 accrual design29 was
used at each dose considered with goal
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death or last patient contact (censored
observation). Analysis of EC control,
new BM development, and safety/tolerability was done separately for each arm.
All subjects enrolled in the study who
received at least one dose of ipilimumab
were analyzed.

accrual of up to 12 patients for each arm,
with up to 9 patients accrued from either
Thomas Jefferson University or Ohio
State University. Initially 3 patients were
enrolled at the 3 mg/kg level. If none of
these patients experienced a DLT, enrollment continued to the 10 mg/kg level.
If 1 of the 3 experienced toxicity at that
level, 3 additional patients were accrued
to the initial dose level. While waiting to
complete the toxicity assessment for
each triplet, additional patients could
be accrued on the same dose, although
their outcome was not considered for
dose escalation purposes. No patient was
treated at a higher dose until the 3 or 6
patients completed their toxicity evaluation period at the current dose.
Data were analyzed separately for the
two arms. Kaplan-Meier estimates for
OS and PFS were computed in Stata 14
(StataCorp, College Station, TX). PFS was
analyzed from the date of SRS (or first day
of WBRT) to the date of recurrence or
progression. OS was analyzed from the
date of first RT fraction to the date of

This study was funded by Bristol-Myers
Squibb (New York City, NY) which
provided the study drug and worked
with the senior authors in the design
and analysis. All authors jointly approved
this work for submission and confirm
the accuracy of the data. No additional
authors not listed contributed to this
work. All authors affirm that this trial
was performed in accordance with the
protocol and all amendments.

RESULTS
Patient Characteristics
Of the 26 patients screened for the trial,
17 signed informed consent and were
deemed eligible. One patient never
received protocol therapy due to deteriorating health following consent. Sixteen
patients received study therapy and were
analyzed (Figure 2). Table 1 summarizes
the patient and clinical characteristics,
separately for the two arms. Overall, the
mean age at time of BM diagnosis was 60
(SD, 5-13) and 75% of the patients were
male. There were 8 patients each with
ECOG performance status of 0 and 1.
Nine patients (56%) had initial BM surgery.
Thirteen patients (81%) had EC metastases at the time of BM diagnosis and 5
(38%) received RT for their EC disease.
In Arm A (WBRT, n=5), the median
number of lesions was 6 (range, 1 to >10)
and the dose was 30 Gy in 10 fractions
for all patients. In Arm B (SRS, n=11, the
median number of lesions was 2 (range,
1 to 3) and the median dose was 24 Gy
(range, 15 to 24 Gy). In total, 20 lesions/
cavities were treated with SRS with a
median planning target volume of 3.25
cc per individual lesion (range, 0.1-22.7
cc). The median per patient treatment
volume was 8.5 cc (range 0.5-29.2
cc). The median number of completed
cycles of ipilimumab was as follows: 4
(range, 2 - 4+14 maintenance) for dose
level 3 mg/kg (n=7), and 3 (range, 2 - 4
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Table 1. Baseline Patient, Lesion, and Treatment Characteristics
Characteristic

Value

Patients (n=16)
Mean age at IC diagnosis (range)
Sex, No. (%)
ECOG performance status (n)

Toxicity

Male

13 (81%)

Female

3 (19%)

0

8

1

7

2

1

Ipilimumab in combination with RT
was well tolerated. There were 21
grade 1-2 neurotoxic effects including
the following: headache (n=6, 37.5%),
nausea/vomiting (n=3, 18.8%), subclinical
intracranial hemorrhage (n=4, 25%),
dizziness (n=1, 6.3%), vision changes
(n=1, 6.3%), tinnitus/hearing loss (n=3,
18.8%), facial palsy (n=1, 6.3%), weakness/neuropathy (n=1, 6.3%), and seizure
(n=1, 6.3%). There were no documented
reports of pseudoprogression in our
small sample of patients.

13 (81%)

Number with pre-RT surgery

8 (50%)

Ipilimumab

maintenance) for dose level 10 mg/kg
(n=9). Two patients in both arms received
pre-treatment dexamethasone (mean
dose 6 mg/day and 3.5 mg/day in the SRS
and WBRT arms, respectively).

60 (37-75)

Number with extracranial metastases
Radiation technique

Ipilimumab Trial

WBRT

5 (31%)

Median # lesions (range)

6 (1->10)

SRS

11 (19%)

Median # lesions (range)

2 (1-3)

Median dose, Gy (range)

24 (15-24)

Dose

9

3 mg/kg

Median # cycles completed (range)

4 (2-4+14 maintenance)

Dose

7

10 mg/kg

Median # cycles completed (range)
Median length of follow-up after RT, months (range)

3 (2-4)
9.1 (2-37)

One patient experienced headache
prompting emergency room evaluation,
categorized as a grade 3 neurotoxic
event. This toxicity occurred following
SRS but prior to first IT administration
and was therefore not considered a
dose-limiting toxicity (DLT), but rather,
an effect of surgery and SRS. The patient
went on to receive 4 doses of ipilimumab plus one maintenance cycle prior
to disease progression. There were no
additional grade 3 neurotoxicities.
Table 2 summarizes the AEs in detail.
In addition to the neurotoxicity above,
there were 10 additional grade 3 toxicities, including gastrointestinal most
commonly (n=5, 31%). There were
no grade 4 or 5 toxicities. Of note, no
patients experienced radionecrosis.

Progression-Free Survival and
Overall Survival

Figure 3. Progression-free survival for the SRS and WBRT patients

Published by Jefferson Digital Commons, 2018

Median follow-up time was 8.0 months
in Arm A (range, 3.5 to 24.1) and 10.5
months in Arm B (range, 1.8 to 36.8) from
first day of RT to last follow-up or death.
At time of analysis, no patients were
still on treatment. Fourteen patients in
total progressed and/or died during the
study’s follow-up (5/5 = 100% in Arm
A and 9/11 = 82% in Arm B). Thirteen
patients had IC progression (including
the 6 who subsequently died). Median
time to IC progression was 2.53 months
(WBRT, range 0.3-18) versus 2.45 months
(SRS, range 1-37). Overall response
intracranially as defined by the irRC (15
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Table 2. Adverse effects in SRS (n=11) and WBRT (n=5) arms
Grade 1 – 2

Grade 3

Grade 4

SRS

WBRT

SRS

WBRT

SRS

WBRT

Headache

4

2

1

0

0

0

Post-treatment subclinical intracranial
hemorrhage

4

0

0

0

0

0

Nausea, vomiting, abdominal pain

2

1

0

0

0

0

Fatigue

1

1

0

1

0

0

Hearing loss, otitis, tinnitus

1

2

0

0

0

0

Skin reaction, pruritis

2

3

0

0

0

0

Diarrhea

3

2

4

1

0

0

Insomnia

0

1

0

0

0

0

Anorexia

1

2

0

0

0

0

Hot flashes

0

1

0

0

0

0

Constipation

0

1

0

0

0

0

Lymphopenia

1

0

0

1

0

0

Visual changes

0

1

0

0

0

0

Hypophysitis

0

0

0

1

0

0

Hypertension

0

1

0

0

0

0

Alopecia

0

2

0

0

0

0

Dizziness

0

1

0

0

0

0

Bone pain

0

1

0

0

0

0

Anemia

1

1

1

0

0

0

Thrombocyopenia

1

0

0

0

0

0

Depression

1

0

0

0

0

0

Lipase increase

1

0

0

0

0

0

Weakness, neuropathy

1

0

0

0

0

0

Seizure

1

0

0

0

0

0

Facial palsy

1

0

0

0

0

0

Pleuritic pain, effusion

1

0

0

0

0

0

Abbreviations: SRS=stereotactic radiosurgery; WBRT=whole brain radiation therapy.

evaluable patients) was a follows: irSD
(n= 5, 33%), irPD (n=9, 60%), irPR (n=1,
7%). Following SRS, of the patients who
experienced new BM or progression of
existing BM (n=8), salvage treatment was
as follows: 4 received salvage WBRT, 3
received further SRS, and one patient
received no further IC treatment. All
patients who failed following WBRT
received SRS as salvage.
Median PFS time was 2.5 months in Arm
A and 2.1 months in Arm B (Figure 3).
Six patients died during follow-up (3/5
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= 60% in Arm A and 3/11 = 27% in Arm
B). Cause of death for these patients was
as follows: urosepsis (n=1), cardiac arrest
(n=1), hemorrhagic progression of BM
(n=2), IC progression (n=1), EC progression (small bowel rupture secondary to
tumor, n=1).
Median OS was 8 months in Arm A and
not reached in Arm B (Figure 4).
Of the 13 patients with EC metastases
at the time of BM diagnosis, 3 patients
received targeted RT to the EC disease

with treatment sites as follows: lung (n=2),
thoracic/lumbar vertebrae and lower
leg soft tissue metastasis (n=1). Of the 3
patients with no EC disease at the time of
BM diagnosis, all 3 remained without EC
disease at 2 month follow-up. Overall, 6
patients experienced EC progression at
2 months, 5 patients had stable disease,
3 patients continued with no EC disease,
1 patient had a partial response (after
having her EC disease treated), and 1
patient did not receive systemic imaging
at the 2 month time point.
Seven patients developed new BM (as
differentiated from previously treated BM)
on follow-up imaging (Arm A, n=1 and Arm
B, n=6) with the median time from first RT
fraction to new BM diagnosis of 1.9 months
(range, 0.97 to 8.2). The median time from
first RT fraction to development of new BM
in the one patient having received WBRT
was 8.2 months.

DISCUSSION
To the best of our knowledge, we report
the first prospective phase I study evaluating concurrent ipilimumab with SRS or
WBRT for patients with melanoma BM.
The toxicity profile of escalating doses
of ipilimumab demonstrated no grade
4/5 toxicity, radionecrosis, or DLTs. Ipilimumab 10 mg/kg with SRS is safe and we
recommend this dose for further study
with concurrent SRS. Additional phase I
studies will be necessary to determine
the safety of WBRT with ipilimumab 10
mg/kg, as we had to terminate this part
of the trial due to slow accrual, however
safety was demonstrated with concurrent WBRT and ipilimumab 3 mg/kg.
CA184-04230 was a phase II trial that
evaluated ipilimumab in patients with
melanoma BM. Patients were specifically
excluded from the trial if they received
any RT within 14 days of ipilimumab
and only 8% of patients had received
prior SRS. There were no unexpected
toxicities and activity was demonstrated
particularly when BM were small and
asymptomatic.30 However, this trial does
not specifically evaluate the safety of
concurrent RT and ipilimumab.
Hodi et al18 reported a large study evaluating 676 patients randomized to receive
ipilimumab 3 mg/kg in combination
with an investigational peptide vaccine
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Seven of the 13 patients treated concurrently had documented hemorrhage
partially accounting for the enlargement and 2 lesions had documented
recurrence. Of note, the IT was not
standardized in this retrospective review
and included ipilimumab, nivolumab,
and pembrolizumab. 32

Figure 4. Overall survival for the SRS and WBRT patients

(gp100), ipilimumab alone, or gp100
alone. OS was 10.0 months in patients
receiving ipilimumab plus gp100,
compared to 10.1 months in the ipilimumab alone arm and 6.4 months in the
gp100 alone arm (p<0.001). Eighty-two
patients (12.1%) had CNS disease in this
study.18 This data is comparable to our
study with the median OS not reached
in the SRS arm and 8 months in the
WBRT arm (median follow-up 10.5 and
8 months, respectively). Given that OS
has not been reached in the SRS arm
of our trial, we hypothesize that the
timing of ipilimumab in close proximity
to SRS may mechanistically promote
duration and intensity of response in
these patients, although this study is
hypothesis-generating in that regard.
To this end, a recent report by Johnson
et al. 31 demonstrated the impact of
systemic agents on the clinical outcomes
of patients with BM. Although this review
included patients with many primary
tumor types, and a variety of agents
(BRAF inhibitors, ipilimumab in patients
with melanoma primaries), the authors
did show that patients receiving IT
with SRS compared to SRS alone had a
median survival of 18 versus 7 months

Published by Jefferson Digital Commons, 2018

and a 1-year OS of 65% versus 30%
(p<0.0001). 31
In terms post-RT lesion size, reports with
combined therapy have been conflicting.
Qian et al.8 recently reported results
regarding 313 melanoma BMs in 53
patients treated concurrently (defined
as RT and IT delivery within 4 weeks
of each other).8 IT was as follows: 54
patients (72%) received anti-CTLA-4
and 21 patients (28%) received antiPD-1. No patients received combination
IT. The median percent reduction in
lesion volume was significantly greater
for the concurrent group. The timing
of IT and SRS did not appear to effect
post-treatment lesion size. 8 In this
report, only 39 lesions in 24 patients
demonstrated regrowth to >120% baseline volume. Authors concluded that the
early response is greater and more rapid
with concurrent therapy. There was not
specific mention of tumor hemorrhage
in this study.8 In contrast to this report,
preliminary data reported by Shen et al.
showed an increase in lesion size in 13 of
26 lesions treated concurrently (defined
as IT starting “prior to or with SRS”). 32
Lesion enlargement in the SRS alone
cohort occurred with similar frequency.

Kiess et al. 33 retrospectively reported
response and toxicity on 46 patients with
melanoma BM who received ipilimumab
(3 mg/kg or 10 mg/kg) with SRS (median
dose 21 Gy) between 2005 and 2011.
Patients treated with SRS either before
or during ipilimumab had improved OS
compared to those having SRS afterward
(1-year OS 56% vs 65% vs 40%, p=0.008).
Moreover, only approximately 20% of
patients experienced grade 3 or 4 toxicities.
Interestingly, SRS before or during IT was
more likely to be associated with a temporary increase in size or hemorrhage of the
irradiated lesion, likely secondary to inflammation, and asymptomatic in the majority
of cases.33 Most likely due to the small
numbers in our study and the frequency
of neurosurgical intervention prior to SRS
(6/11 patients, 55%), we did not observe the
same temporary lesional edema following
combination therapy. Similarly, no lesions
were deemed to undergo pseudoprogression following SRS.
When evaluating the effects of IT, EC
disease control is also of interest. First
described in the 1950s, the abscopal
effect refers to the seldom-reported
phenomenon of tumor regression of a
secondary site following RT to a separate primary site.34 Seromic analysis and
immunologic correlates of the abscopal
effect in a patient with melanoma has
demonstrated antigenic targets with
increased antibody responses following
RT.35 The surprising response achieved
by the patient in this report provided new
insight in the mechanisms of combination therapy. Our study evaluated EC
control as a secondary endpoint with
a similar hypothesis that IT delivered in
close proximity to SRS may impact distant
control. In our study, we did not observe
the abscopal effect extracranially or intracranially at non-target sites.
Limitations of our study include slow
accrual to Arm A, leading to its early closure.
This arm did show safety with ipilimumab 3
mg/kg, however. An additional caveat to
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Table 3. Previously reported series of melanoma brain metastases treated with immunotherapy.
Primary
author

Year

Analysis type

Primary

Patients IT agent/timing
who got
SRS (n)

Patients
receiving IT
and SRS (%)

Median
survival
(months)

OS

Other

Knisely41

2012

Prospectively
collected,
retrospectively

melanoma

7

27 (35%)

21.3 (with IT)
v. 4.9 (no IT)

2 year: 47.2%
(with IT) v.
19.7% (no IT)

Grade ≥3
toxicity NR

Ipilimumab (SRS first,
n=16; IT first, n=11)

p=0.044
3

Johnson

Kiess3

2015

2015

retrospective

retrospective

renal cell,
737
melanoma,
breast, colon,
esophagus,
lung

various agents
(including BRAF
inhibitors &
ipilimumab), IT
concurrently or within
30 days of SRS

167 (23%)

melanoma

Ipilimumab (concurrent, n=15; SRS first,
n=19; IT first, n=12)

46 (100%)

46

18 (with IT)
v. 7 (no IT)

1 year: 65%
(with IT) v.
30% (no IT)

Grade ≥3
toxicity NR

p<0.0001

12.4
(all patients)

1 year: 65%
(concurrent)
v. 56% (SRS
before) v. 40%
(IT before)
P=0.008

1 year
RR: 69%
(concurrent)
v. 64% (SRS
before) v.
92% (IT
before)
P=0.003

Patel42

2015

retrospective

melanoma

54

Ipilimumab (within 4
months of SRS)

20 (37%)

9.1 (with IT) v. NA
8.0 (no IT)
p=0.84

1 year LC:
71.4% (with
IT) v. 92.3%
(no IT)
p=0.40

NR: not reported; IT: immunotherapy; RR: regional recurrence

our study is that ipilimumab alone is no
longer the standard of care for previously
untreated advanced melanoma. First-line
therapy is now either anti-programmed
death 1 (PD-1) inhibitor monotherapy
(pembrolizumab or nivolumab) or a
combination of nivolumab with ipilimumab.36 This combination of therapies
improved overall response rate and
PFS as compared with either treatment
alone, however, demonstrated significantly increased toxicity. Compared
to single agent therapy, the effect of
combination therapy on OS has not yet
been demonstrated.37,38 Pembrolizumab
alone demonstrated prolonged PFS and
OS and had less high-grade toxicity as
compared to ipilimumab in patients with
advanced melanoma as demonstrated in
the KEYNOTE-006 trial.39 Based on these
results, future studies will need to address
RT with combination checkpoint inhibitor
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therapy or pembrolizumab alone.
An additional limitation is the relatively
short follow-up possibly limiting the
capture of late toxicity. The median
follow-up in the arm receiving SRS was
10.5 months which may be long enough
to catch some, but not all cases of radionecrosis. A recent report by Colaco et
al.40 evaluating 180 patients with BM who
received radiosurgery with either cytotoxic chemotherapy, targeted therapy,
or IT noted a significantly increased rate
of radionecrosis or treatment-related
imaging changes in the IT group (OR
2.40 [95% CI 1.06–5.44]; p = 0.03).40 The
median follow-up was 11.7 months and
31% of patients had melanoma primaries.
Of importance, 30% of patients received
prior WBRT which increases one’s risk
for subsequent radionecrosis following
radiosurgery. For patients who received
IT alone, median time to radionecrosis

development was 10.2 months (range,
2.8-22.1 months), which is slightly shorter
than the median follow-up in our SRS
arm.40 Therefore, although our study
does have relatively short follow-up, it is
worthwhile to demonstrate that we have
no documented cases of radionecrosis.
In an era where combined modality
targeted therapy is becoming more
promising and increasingly utilized, it is
important to establish the safety profiles
of these modalities.41 Our results demonstrate the safety of combining SRS with
either ipilimumab 3 mg/kg or 10 mg/kg.
Future exploration of multi-agent immunotherapy in combination with SRS for
melanoma BM is warranted, although
currently there are no clinical trials open
to accrual evaluating the safety and efficacy of this combination of treatment.
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INTRODUCTION
Evolution of Transsphenoidal Surgery
Since the initial description of a transnasal approach for the treatment of pituitary
tumors in 1907, transsphenoidal surgery has undergone a continuous evolution marked
by close collaboration between neurosurgeons and otolaryngologists. Oskar Hirsch,
developed a lateral endonasal approach in 1910 that he initially performed as a five step
procedure over a several week period before simplifying the procedure to a singlestep submucosal transseptal approach.1 Contemporaneously, Harvey Cushing began
approaching pituitary tumors using a transsphenoidal approach but transitioned to the
transcranial route due to his concern that an endonasal approach provided restricted
access and poor illumination, compromising adequate decompression of the optic
apparatus.2 Most neurosurgeons followed Cushing’s lead and transsphenoidal surgery
was not “rediscovered” until Jules Hardy introduced the surgical microscope in the
1960s.3
The first completely endoscopic transsphenoidal approach for pituitary tumors was
reported in 1992 by Jankowski and further advanced by the collaborative teams of
Jho and Carrau in Pittsburgh and Sethi and Pillay in Singapore.4,5 Over the last 20
years, the endoscopic technique has been adopted by a multitude of surgeons who
have favored the dynamic panoramic view afforded by the endoscope, allowing for
improved visualization and better resection of tumors extending into the suprasellar
area and cavernous sinuses. Additionally, the advent of extended endoscopic endonasal
approaches, such as the trans-planum and lateral trans-cavernous, has facilitated resection of large, invasive pituitary tumors that were previously deemed unresectable or
requiring transcranial surgery.

Critics of the endoscopic approach have
rightfully focused on the loss of stereoscopic vision as a major limitation with
mastery of the procedure demanding a
steep learning curve. Prospective studies
directly comparing the microscopic
and endoscopic approaches for pituitary tumors have not been performed,
however, an increasing body of literature
has established the safety and non-inferiority of endoscopic endonasal techniques
and several studies have demonstrated
improvement in the extent of tumor
resection. McLaughlin et al. reported
that following microsurgical resection of
pituitary adenomas, endoscopy revealed
residual tumor leading to further resection in 36% of cases.6 Messerer et al.
found their gross total resection rate
increased from 50% utilizing the microscope to 76% upon initial conversion to
the endoscopic approach.7 In this review,
we describe the principles of pituitary
surgery including the key-elements of
surgical decision-making and discuss
the technical nuances distinguishing
the endoscopic from the microscopic
approach.

PRINCIPLES OF SURGERY
Indications for Surgery

Figure 1. Nasal stage.
A. “1.5” approach to the sphenoid sinus with wide ipsilateral sphenoidotomy and limited
contralateral sphenoidotomy with preservation of inferiorly located sphenopalatine arterial supply to the nasoseptal flap. B. “Tunnel” approach for patients with septal spurs with
ipsilateral wide sphenoidotomy and submucosal elevation of septal mucoperichondrium.

Published by Jefferson Digital Commons, 2018

Pituitary adenomas are most frequently
categorized as functional or nonfunctional depending on their hormonal
secretory pattern. Prolactinomas represent the most common functional
adenoma and the mainstay of treatment
is dopamine-agonist medical therapy,
with surgical treatment reserved for
patients who fail to respond despite
dose-escalation or are intolerant to the
medications. Transsphenoidal surgery
remains the primary treatment for
adenomas secreting ACTH (Cushing’s
disease) and growth-hormone (acromegaly) with biochemical remission rates
significantly correlated with tumor size
and invasiveness.7
Non-functional pituitary adenomas
(NFPA) are extremely common —
autopsy and radiographic studies reveal
the presence of NFPA in 11-27% of the
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population (8,9). While most NFPA are
microadenomas (<1cm) and clinically
asymptomatic, macroadenomas may
present with compressive symptoms
including headache, visual impairment,
hormonal insufficiency, and cranial nerve
palsies due to cavernous sinus extension. Surgery is generally indicated for
patients with macroadenomas causing
visual compromise or exhibiting growth
on serial imaging studies. Approximately
5% of patients with pituitary adenomas
present with apoplexy due to intratumoral
hemorrhage or infarction.10

Preoperative Surgical Planning
The main goal in endoscopic pituitary
surgery is to maximize tumor resection
while avoiding complications such as
visual deterioration, cerebrospinal fluid
(CSF) leakage, endocrinopathy, vascular
injury, and sinonasal morbidity. Although
pituitary adenomas are typically benign
lesions, recurrences are common
following incomplete surgical removal
and thorough preoperative surgical
planning is essential to achieve optimal
outcomes.
Magnetic resonance imaging (MRI)
studies reliably delineate the size and
extension of pituitary tumors, with the
notable exception of some ACTHsecreting microadenomas that may be
radiographically occult. Inspection of
the preoperative MRI provides an assessment of the likelihood of gross total
resection primarily based on cavernous
sinus extension as well as a prediction
of the surgical challenges that will be
encountered such as intraoperative CSF
leakage and a narrow surgical corridor
due to reduced distance between the
parasellar carotid arteries. Large tumors
that extend vertically within the suprasellar area may significantly compromise
the diaphragma sellae or even invade
the ventricular system resulting in highflow CSF leaks requiring more extensive
repairs such as nasoseptal flap (NSF)
placement, lumbar drainage, or use of
autologous tissues (e.g., fascia lata or
adipose tissue). As discussed in more
detail later, preoperative anticipation
of the need for a NSF is critical as the
flap must either be harvested during the
initial nasal stage of the approach or the
vascular pedicle to the flap preserved
such that a viable flap can be harvested
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later should it prove necessary. Additionally, detection of the position of the
normal compressed pituitary gland on
the pre-operative MRI assists with the
preservation of hormonal function as
intraoperative distinction of the gland
from tumor based on color and consistency differences is frequently subtle.
Computed tomography studies provide
complementary information helpful in
surgical planning. Coronal and sagittal
reconstructions reveal bony changes
such as erosion of the sellar floor and
dorsum and can be used intraoperatively
for image guidance, especially in patients
with altered sinonasal anatomy related
to prior surgery. Similarly, we have found
preoperative nasal endoscopy helpful
to optimize our surgical plan and avoid
complications related to paranasal sinus
disease or anatomic variability. Typically,
chronic rhinosinusitis does not represent
an absolute contraindication to transsphenoidal surgery, however, patients
with acute rhinosinusitis, especially those
with fungal disease, should be treated
appropriately prior to elective surgery.11
Otolaryngology preoperative evaluation
is critical in patients with acromegaly
who frequently present challenges for
airway management during surgery due
to soft tissue hypertrophy and bony
abnormalities.12

Surgical Approach: Nasal Stage
The endoscopic surgical approach for
pituitary tumors can be divided into the
nasal, sphenoidal, and sellar stages. Since
the inception of our endoscopic skull base
program at Thomas Jefferson University
in 2005, we have advocated for a team
approach between otolaryngology and
neurosurgery. The complementary skill of
experienced sinus and pituitary surgeons
has enabled us to optimize oncologic
outcomes and minimize complications,
both minor and major. Our approach to
pituitary surgery has evolved and we have
adopted a tailored approach to these
tumors based on their size, invasiveness, and secretory pattern allowing us
to minimize sinonasal disruption without
compromising tumor resection.
Patients are positioned supine with the
head on a gel headrest. Neuronavigation
is used routinely to help guide the surgical
approach and assess the adequacy of

tumor resection with co-registration of
the preoperative CT and MR images using
facemask fiducials. Although neuronavigation is valuable, over-reliance on this
adjunct and a failure to correlate with
anatomic landmarks can lead the surgeon
off course. The head is slightly elevated to
reduce mucosal congestion and venous
oozing/bleeding during the approach.
We do not routinely prepare the skin of
the face or nasal cavity with antiseptic
solution, but graft sites such as the lateral
thigh for fascia lata or adipose tissue
should be prepared in a sterile standard
fashion.
The turbinates are gently lateralized with a
blunt instrument. Although routine resection of the middle turbinates is favored
by some surgeons to increase the nasal
working corridor, we have found that
turbinate lateralization combined with
a limited posterior septectomy provides
more than sufficient access to the sella
for pituitary tumor resection and minimizes post-operative patient sinonasal
morbidity.13,14 A binarial approach is typically performed allowing for two surgeons
to work simultaneously with up to four
instruments in the field, including the
endoscope. In our experience, a pedicled
nasoseptal flap (NSF) is rarely necessary
for cranial base repair during standard
transsellar pituitary adenoma resection,
however, in certain cases the need for
a NSF is unanticipated or may become
necessary during future surgeries.15 As
such, we advocate at least unilateral preservation of the NSF whenever possible
and have described a variety of tailored
approaches to the sphenoid sinus that
enable NSF preservation applicable to
endoscopic pituitary surgery. Our standard approach, termed the “1.5 approach”,
involves an ipsilateral wide sphenoidotomy (“1”) on the working instrument
side with a limited contralateral sphenoidotomy (“0.5”) on the endoscope side
(Figure 1A). The limited sphenoidotomy
is performed by extending the natural
sphenoid os superiorly with Kerrison
rongeurs, thus preserving the more
inferiorly located sphenopalatine artery
supply to the nasal septal mucoperiosteum and mucoperichondrium. Addition
of a limited posterior septectomy (typically 1cm) allows communication of the
binarial sphenoid exposures and provides
ample working room and maneuverability
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(unpublished data). In patients with nasal
obstruction due to septal deviation
or large spurs, a “tunnel approach” is
performed involving a septoplasty and
submucosal “tunnel” with a wide contralateral sphenoidotomy (Figure 1B). The
approach begins with a standard hemitransfixion incision used for septoplasty
and the septal mucoperichondrium is
raised and extended posteriorly over the
vomer and laterally along the sphenoid
rostrum. A septoplasty or spur removal is
then performed, with the resultant unilateral “tunnel” analogous to the standard
microscopic transeptal approach with
preservation of the NSF ipsilaterally. On
the contralateral side, a wide sphenoidotomy is performed. If NSF harvest proves
necessary, the superior and inferior incisions for the flap can be performed and
elevation completed on the “tunnel” side.
The NSF harvest and replacement (“raise
and return”) approach involves a standard harvest of the NSF combined with
a wide contralateral sphenoidotomy. We
typically reserve this approach for cases
in which there is a high likelihood of
NSF utilization such as tumors with very
significant vertical suprasellar extension
or that extend anteriorly over the planum
where, depending on tumor consistency,
an extended endonasal approach may
become necessary for complete tumor
resection. This approach is also used
for cases with potential for a high-flow
CSF leak. If cranial base repair with the
NSF proves unnecessary, the flap can
be returned to its native position along
the septum. These “raised and returned”
flaps tend to heal quite well with minimal
crusting and post-operative discomfort.
We do not advocate routine harvest
of the NSF, however, as this technique
is associated with increased sinonasal
morbidity including the possibility of
olfactory dysfunction, septal perforation,
and sensory loss due to superior alveolar
nerve injury. A variety of authors have
described “rescue flap” modifications
where the nasoseptal flap is partially
raised during the nasal stage such that the
vascular pedicle is preserved, although
these modifications have been associated in some cases with increased risk of
olfactory loss.16,17
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Surgical Approach: Sphenoid Stage
The anatomy of the sphenoid sinus is
highly variable in regard to its bony septa
and pneumatization. The configuration
of sphenoid sinus pneumatization can
significantly affect access to the sella.
The pneumatization of the sphenoid
sinus is usually completed by age ten and
the majority of adults possess the wellpneumatized sellar pattern.18 The sellar
floor lies along the posterior wall of the
sphenoid sinus within the midline and
the importance of maintaining a midline
orientation cannot be overstated. In addition to the sellar prominence, anatomic
landmarks along the posterior sphenoid
wall include the medial and lateral opticocarotid recesses, parasellar carotid
prominences, and clival recess. Frequently,
the entirety of these landmarks may not
be plainly apparent and careful attention
to the preoperative imaging combined
with judicious use of neuronavigation will
prevent inadvertent complications. The
intra-sphenoidal septa should be taken
down with use of the high-speed drill or
Thru-cutting instruments, avoiding any
fracturing or rotational maneuvers as
these septa often have posterior attachments along the carotid prominences.
Additionally, anticipating the presence
of Onodi air cells will prevent injury to
the optic nerves. Endoscopic transsphenoidal pituitary approaches can be
safely performed in children and adults
with the conchal and pre-sellar variant
patterns, but prolonged drilling will be
required along with an increased reliance
on neuronavigation.
The sella is typically expanded in the
presence of macroadenomas and the
bony floor may be thinned or absent.
Conversely, microadenomas do not
cause expansion or thinning of the sellar
floor, often requiring bone removal with
a diamond burr to access the dura. The
sphenoid mucosa should be stripped
from the sellar floor bluntly or with
gentle bipolar cautery prior to drilling
the sella. Monopolar cautery may lead
to optic nerve or carotid injury and its
use is highly contraindicated along the
posterior sphenoid wall. If a NSF will be
placed for repair, further mucosal stripping
should be performed to prevent delayed
mucocele development by trapping
mucosa under the flap. Bony removal of
the sellar floor is usually performed with
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rotatable Kerrison rongeurs after a pilot
bony opening has been created with the
drill or Cottle elevator. As opposed to the
microscopic approach where all but the
central portion of the intrasellar tumor is
removed based on “feel”, bony removal
for the endoscopic approach needs to be
more extensive to maximize the visualization benefits of the endoscope and allow
for tumor dissection. In the endoscopic
approach, the anterior wall of the sella
should be removed to the medial edges
of the cavernous sinuses bilaterally and
extended superiorly to the intracavernous
sinus in the region of the tuberculum sella
(Figure 2A). The amount of bony removal
of the sellar floor is variable, however,
for tumors with significant suprasellar
extension additional removal of the floor
allows for introduction of more vertically
angled instruments helpful in removing
tumor that fails to descend into the sella
following debulking. For tumors that
clearly invade the cavernous sinuses,
further lateral bony removal across the
anterior face of the parasellar carotid
arteries can be performed.

Surgical Approach: Sellar Stage
The exposed dura of the sella is then
opened in a cruciate fashion with a
retractable knife and angled scissors.
Horizontal cuts should be made in a
lateral-to-medial direction to avoid carotid
injury while the vertical incision should
be made in a superior-to-inferior direction to avoid inadvertent entry into the
anterior arachnoid cistern with resultant
CSF leakage (Figure 2A). The principles
of tumor removal differ for micro- and
macro-adenomas. Historically, pituitary
adenomas have been resected in a piecemeal fashion using a variety of blunt ring
curette-type instruments. Oldfield et al.,
however, demonstrated the advantages of
dissection of the histologic pseudocapsule
surrounding pituitary adenomas, allowing
microadenomas to ideally be resected in
an en-bloc extracapsular fashion (Figure
2B).19 When feasible, en bloc resection
reduces the likelihood of tumor remnants
and increases biochemical remission for
functional adenomas.20 Rarely, in patients
with Cushing’s disease, a pituitary microadenoma may not be visible on MR
imaging but the diagnosis confirmed by
adrenocorticotropic hormone (ACTH)dependent elevation of cortisol levels and
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System, NICO corp.) extremely helpful in
performing tumor debulking with location of the carotid arteries repetitively
confirmed with neuronavigation and
the micro-Doppler. In rare cases where
adequate decompression cannot be
safely performed through a standard
transsphenoidal transsellar opening,
we convert to an extended endoscopic
approach (EEA) with drilling of the tuberculum sella and planum. The additional
bony removal and more anterior dural
opening enables tumor to be dissected
from the optic nerves and chiasm under
direct visualization but requires more
extensive skull base repair.

Figure 2. Microadenoma removal.
A. Bony removal of sellar floor to medial extent of cavernous sinuses bilateral and
cruciate dural opening performed with retractable blade. B. En bloc resection of pituitary
microadenoma with extracapsular dissection. C. Pituitary gland exploration for occult
microadenoma with staged vertical and horizontal gland incisions.

high-dose dexamethasone suppression.
In these cases, ACTH levels are measured
from the inferior petrosal sinuses using
invasive catheters to determine the likely
side of the adenoma within the sella. The
pituitary gland is then explored systematically using a series of horizontal and
vertical incisions to identify the adenoma
beginning on the presumptive side
(Figure 2C).
En bloc resection of macroadenomas is
rarely possible and we advocate a strategy
of systematic internal debulking followed
by extracapsular dissection along the
cavernous sinus walls and diaphragm. As
shown in Figure 3, the inferior aspect of the
tumor is first debulked with ring curettes
in the midline before extending posteriorly
to the dorsum sella and laterally toward
the medial cavernous sinus walls. Pituitary
adenomas are frequently soft tumors and
overzealous interior debulking can lead to
premature diaphragma sellae herniation
with subsequent trapping of tumor within
the folds of the collapsed arachnoid.
Manipulation of the diaphragm in order to
complete tumor removal from these folds
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often leads to compromise and intraoperative CSF leakage. To avoid this, the lateral
superior recesses should be debulked
prior to continued midline debulking.
Once the tumor has been adequately
debulked, the interface between the dura
and the tumor pseudocapsule is defined
with angled curettes and developed
in an extracapsular fashion toward the
medial cavernous sinus wall. For tumors
without true cavernous sinus invasion,
this pseudocapsule can be dissected
circumferentially and then brought down
away from the diaphragm. The transition
zone between the normal gland and the
tumor must be anticipated and carefully
developed to avoid injury to the gland
and resultant pituitary insufficiency.
Infrequently, pituitary macroadenomas
may be extremely fibrous and resection
of these tumors can be considerably
more dangerous due to the need for
sharp debulking, placing the carotid
arteries and optic apparatus at increased
risk for injury. We have found use of
ultrasonic aspirators and side-cutting
rotatable microdebriders (NICO Myriad

The most frequent areas of tumor
residual following transsphenoidal resection of pituitary macroadenomas are
the cavernous sinuses and suprasellar
area.21 Once tumor resection is felt to
be completed, the sellar cavity is directly
inspected with 30-70° endoscopes,
with careful attention to these areas as
well as for detection of tumor remnants
adherent to the normal pituitary gland.

Figure 3. Macroadenoma removal.
A. Initial debulking with blunt ring
curettes is performed within the midline
inferior extent of the pituitary macroadenoma. B. After interior debulking,
extracapsular dissection of the lateral
aspect of tumor is performed with separation of the tumor pseudocapsule from
the medial wall of the cavernous sinus.
C. Superior extracapsular dissection of
the tumor away from the diaphragma
sellae. D. Symmetric descent of the
diaphragm after complete macroadenoma removal.

30

et al.: Full Issue: Volume 13, Issue 1 - Winter 2018

Pituitary Surgery

Cavernous Sinus Invasion

Figure 4. Dural reconstruction.
A. Intrasellar cavity after tumor resection with incompetent diaphragma sellae and
low-flow CSF leakage. B. Placement of “inlay” synthetic dural substitute beneath leaves
of dura. C. Supplementation of dural graft with tissue sealant. D. Intraoperative view after
dural reconstruction with watertight closure.

Symmetric descent of the diaphragm
into the sella is usually indicative of optic
chiasm decompression and failure of the
diaphragm to descend or asymmetric
descent should prompt further search
for residual tumor. After final confirmation of complete tumor resection,
meticulous hemostasis is achieved with
the use of hemostatic matrix agents and
gentle packing with cottonoids. In our
experience, the most common reason
for postoperative hemorrhage has been
incomplete tumor resection and absolute
hemostasis is necessary when residual
tumor is expected.
A graded approach to dural reconstuction
is performed and in the absence of any
intraoperative CSF leakage as confirmed
by Valsalva maneuver, the dura is simply
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covered with a layer of absorbable
hemostatic cellulose to promote epithelialization. Small dural defects resulting in
low-flow CSF leakage are repaired with a
synthetic dural substitute inlay graft placed
under the leaflets of the dural opening and
supplemented with a thin layer of dural
sealant (Figure 4). For larger diaphragmatic
defects, the arachnoid is directly repaired
with an onlay dural substitute covering
the site of leakage followed by placement of an inlay dural graft and sealant.
For EEA and high-flow leaks related to
entry into the ventricular system, a NSF is
used to buttress the synthetic dural graft
repair or a fascia lata “button” graft repair
as previously described.25 Lumbar drain
placement and nasal packing are rarely
necessary for CSF leak avoidance.

The cavernous sinuses are paired thinwalled venous channels located lateral to
the sella. The internal carotid artery (ICA)
and its branches course within the center
of the channel with the oculomotor,
trochlear, abducens, and trigeminal
cranial nerves located more laterally.
Pituitary adenomas commonly invade
the medial wall of the cavernous sinus
within the carotid siphon with the extent
of invasion predicting the likelihood of
gross total tumor resection. Although
the endoscopic approach provides
improved visualization of tumor within
the cavernous sinus, complete resection
remains challenging.23 In the majority
of patients, the presence of residual
benign adenoma within the cavernous
sinuses can be managed expectantly or
with radiation therapy (e.g., stereotactic
radiosurgery or stereotactic radiotherapy)
with control rates for non-functional
tumors typically around 90%.24 Tumor
control rates following radiosurgery
are significantly reduced, however, for
larger volume tumors demonstrating the
importance of maximal surgical debulking
prior to radiation treatment. Biochemical
remission rates for functional adenomas
are significantly lower than tumor control
rates with remission achieved in only
approximately half of patients with Cushing’s disease and acromegaly.25 As such,
more aggressive resection of functional
tumors invading the cavernous sinus is
often appropriate with the goal of either
achieving complete resection or reduction of the residual tumor volume for
subsequent radiosurgery.
Surgical approaches to the cavernous
sinus include the medial and lateral
approaches. The medial approach (Figure
5A) is a continuation of the standard
transsphenoidal approach but involves
following the adenoma through the
cavernous sinus medial wall breach. To
increase access to the cavernous sinus,
the sellar bony opening is extended
laterally across the anterior face of the
carotid artery. Intrasellar tumor resection is completed before entry into
the cavernous sinus. The cavernous
sinus should be approached through
the contralateral nare using angled
ring curettes and suctions to optimize
the angle of attack with visualization
performed using a 30-70° endoscope.
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aspect of the cavernous sinus. Careful
evaluation of the preoperative CT images
helps determine the access to the lateral
cavernous sinus and in some patients
with large, well-pneumatized sphenoid
sinuses, access may be achieved through
the lateral sphenoid sinus recess without
extensive pterygoid drilling. After carotid
artery localization with the microDoppler, the dura is opened sharply and
tumor resected. A multi-layered closure
with NSF coverage is then performed.
The most feared and potentially devastating morbidity with the cavernous
sinus approaches is ICA rupture with
the likelihood of injury increased with
fibrous tumors and prior irradiation.
Management of carotid artery injury will
be more extensively discussed in other
chapters of this edition but typically
requires intraoperative control using
direct compression followed by vessel
sacrifice in the interventional angiography suite. 26

CONCLUSION
Figure 5. Cavernous sinus approaches.
A. Medial cavernous sinus approach with widened bony opening over carotid
prominence and tumor debulking through the medial cavernous sinus wall with
angled endoscopes and curettes. B. Lateral cavernous sinus approach with removal of
pterygoid process after ipsilateral ethmoidectomies. After maximal debulking of the
tumor within the sella and medial aspect of the cavernous sinus, the carotid artery is
localized with the micro-Doppler and the lateral cavernous sinus wall opened sharply
for further macroadenoma removal.

Further opening of the medial cavernous
wall may be required to allow for instrument entry and is done using sharp
dissection after the exact position of
the carotid artery has been confirmed
with Doppler ultrasonography. Vigorous
venous bleeding is expected following
removal of tumor from the cavernous
sinus and is usually easily controlled with
hemostatic matrix agents.
A lateral cavernous sinus approach may
be considered in patients harboring functional adenomas or who have failed prior
radiation with the bulk of their cavernous
sinus tumor volume lateral to the carotid
artery, although the risk of cranial
nerve and ICA injury are significantly
increased with this approach (Figure
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5B). Fortunately, the majority of cranial
nerve palsies are transient, resolving
within several weeks or months, and use
of electrophysiologic monitoring of the
oculomotor, trochlear, and abducens
nerves may further reduce the likelihood of permanent injury. To access
the region lateral to the carotid artery,
a wide lateral sphenoid sinus exposure
is necessary often with a transpterygoid
extension. During the nasal stage, a
complete unilateral anterior and posterior ethmoidectomy is performed after
removal of the middle turbinate. The
vidian canal is identified in the lateral
floor of the sphenoid sinus and the
superomedial aspect of the pterygoid
process is removed to expose the lateral

Endoscopy represents the most recent
evolution of transsphenoidal surgery.
Although the endoscopic approach
has not been proven to be superior to
the classical microscopic approach
for resection of pituitary adenomas,
the benefits of endoscopy become
most apparent during removal of large,
invasive tumors where the panoramic
visualization afforded by the endoscope
allows for more complete resections
to be performed. As neurosurgeons
continue to take on the challenge of
endoscopy and surmount their learning
curve, endoscopic transsphenoidal
surgery for pituitary adenomas will
certainly become the standard.
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Key Points
1. Understand the principles of pituitary
surgery including the key-elements of
surgical planning and decision-making
2. 
I dentify the technical nuances
distinguishing the endoscopic from
the microscopic transsphenoidal
approach
3. 
Understand the strategies utilized
during the nasal, sphenoidal, and
sellar stages of surgery that maximize
tumor resection while minimizing
complications and preserving sinonasal anatomy/function
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other than “maximal safe resection” as
mentioned previously.

1

Standard preoperative images can be
analyzed for macroscopic shape and
location features that are associated with
improved survival,10-13 providing potential
biomarkers that may be utilized in stratifying patients in clinical trials.
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INTRODUCTION
In 2017, it is estimated that 26,070 patients will be diagnosed with a malignant primary
brain tumor in the United States, with more than half having the diagnosis of glioblastoma (GBM).1 Magnetic resonance imaging (MRI) is a widely utilized examination in the
diagnosis and post-treatment management of patients with glioblastoma; standard
modalities available from any clinical MRI scanner, including T1, T2, T2-FLAIR, and
T1-contrast-enhanced (T1CE) sequences, provide critical clinical information. In the
last decade, advanced imaging modalities are increasingly utilized to further characterize glioblastomas. These include multi-parametric MRI sequences, such as dynamic
contrast enhancement (DCE), dynamic susceptibility contrast (DSC), diffusion tensor
imaging (DTI), functional imaging, and spectroscopy (MRS), to further characterize
glioblastomas, and significant efforts are ongoing to implement these advanced imaging
modalities into improved clinical workflows and personalized therapy approaches. A
contemporary review of standard and advanced MR imaging in clinical neuro-oncologic
practice is presented.

Initial diagnosis and surgical management
Most patients with glioblastoma undergo computed tomography of the brain upon
initial presentation. Once a mass is identified and hemorrhage is excluded, a contrastenhanced MRI is typically ordered, with standard T1, T2, FLAIR, and contrast-enhanced
T1 (T1CE) sequences.2,3 Many institutions will also capture gradient echo and diffusion
sequences. Maximal safe debulking surgery is recommended as the initial standard of
care. Neurosurgeons will often utilize high-resolution MRI (0.5 – 1.2mm slice thickness)
for surgical planning and intraoperative guidance, as well as to make the determination
of how aggressively to resect based on risk of toxicity to nearby eloquent regions.4
Standard imaging also can identify other important characteristics of the mass in situ,
including the amount of necrosis, compression of the surrounding normal tissue, and
midline deviation.
A recent meta-analysis of over 40,000 glioblastoma patients demonstrated that grosstotal resection was associated with improved survival as compared to subtotal resection.5
Historically, the determination of gross-total resection was made in the operating room
by the neurosurgeon. However, in the modern era, the practice of obtaining a postoperative contrast-enhanced MRI within 24-48 hours of surgery has become routine
after publication of a study showing that radiological determination of the extent of
resection via MRI had prognostic significance.6 Several series have attempted to quantify
a threshold value for the extent of resection as a guide for neurosurgeons, utilizing
the amount or enhancing tumor present in the preoperative and post-operative T1CE
images. These series report thresholds ranging from 70% to 100%7-9, with the caveats
that they were obtained retrospectively. To date, no formal threshold is recommended
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Advanced MR imaging sequences have
utility in the preoperative domain as
well. Functional imaging (fMRI) has
been particularly useful in preoperative
surgical planning in cases where tumors
or their resection may disrupt eloquent
areas. Many patients who were once
felt to be unresectable due to uncertain risk of neurologic compromise are
now candidates for more aggressive
resection after functional mapping.14
Diffusion tensor imaging (DTI) generates
rich white matter tractography images
which may guide neurosurgical planning15 and can help distinguish between
post-operative vascular damage and
residual enhancing tumor.16 Dynamic
contrast-enhanced (DCE) sequences
in the preoperative setting measure
pharmacokinetic parameters of contrast
uptake, which may be associated with
early disease progression and survival.17
Dynamic susceptibility contrast (DSC) MR
imaging may be helpful in preoperative
diagnosis18 of malignant lesions. Imaging
features extracted from standard and
advanced preoperative MR sequences
can predict survival, molecular subtype,
and mutational status in glioblastoma,19,20
potentially enhancing the set of imaging
biomarkers available to clinicians.

Post-operative imaging and
radiation planning
After maximal safe resection, which is
evaluated on immediate post-operative
MRI, the standard of care for patients
with glioblastoma is chemoradiation
with concurrent temozolomide, after
the results of a large randomized Phase
III trial. 21 Typically, chemoradiation
begins 3-6 weeks after surgery to allow
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Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 1. Axial CT image at the level of basal
ganglia demonstrates a large heterogeneous
mass in the right frontal lobe with mass effect
on the right lateral ventricle and leftward shift
of midline. Ct, computed tomography.
Figure 2. Axial FLAIR weighted image at the
level of basal ganglia demonstrates heterogeneous mass centered in the right frontal lobe
and basal ganglia with surrounding infiltrating
signal abnormality ‘FLAIR envelope’ which
extends medially across the corpus callosum
posteriorly in the insular region. The ‘FLAIR
envelope’ is typically a manifestation of
combination of tumor infiltration and edema.
There is associated mass effect on the right
ventricle and leftward midline shift. FLAIR,
fluid-attenuated inversion recovery.
Figure 3. Axial gradient echo (GRE) image
depicts multiple foci of hypointense signal
‘susceptibility artifacts’ within the right frontal
mass compatible with intra-tumoral blood
products.
Figure 4. Post gadolinium based contrast
administration T1 weighted axial image
(T1CE). There is heterogeneous irregular

Published by Jefferson Digital Commons, 2018

peripheral enhancement associated with
the right frontal lobe mass with central
non-enhancing area, consistent with
necrosis. Of note are additional patchy areas
of enhancement in the right anterior frontal
lobe and right basal ganglia region. These
additional areas of enhancement lie within
the previously described region of ‘FLAIR
envelope’. FLAIR, fluid-attenuated inversion
recovery; T1CE, T1 contrast-enhanced.
Figure 5. BOLD fMRI for localization of hand
sensorimotor cortex in a patient with right
frontal glial neoplasm. BOLD fMRI data is
superimposed on sagittal FLAIR weighted
image for anatomic localization. In the right
hemisphere, the hand sensorimotor cortex
(arrow) is located along the posterosuperior
aspect of the frontal mass and is separated by
less than one gyrus distance. fMRI, functional
magnetic resonance imaging; FLAIR, fluidattenuated inversion recovery.
Figure 6. BOLD fMRI for localization of
tongue sensorimotor cortex. BOLD fMRI data
is superimposed on axial FLAIR weighted
image for anatomic localization. In the right
hemisphere, the area of

activation (arrow), tongue sensorimotor
cortex is in immediate proximity of the posterior margin of the right frontal mass. FLAIR
envelope seems to extend into this region
of activation. fMRI, functional magnetic
resonance imaging; FLAIR, fluid-attenuated
inversion recovery.
Figure 7. BOLD fMRI for localization of
Broca’s area in a patient with right frontal
glial neoplasm. There is bilateral Broca’s
area activation on sentence completion and
verb generation tasks (arrows), with the right
hemispheric area of activation located at the
anteroinferior aspect of tumor within one
gyrus distance. fMRI, functional magnetic
resonance imaging.
Figure 8. Color fractional anisotropy map
superimposed on axial FLAIR weighted
image. There is loss of fractional anisotropy
in the expected region of right corticospinal
tract (arrow, blue colored fibers). This tract is
located at the posteromedial margin of the
FLAIR envelope. Loss of fractional anisotropy
may be related edema, infiltration by tumor
or displacement. FLAIR, fluid-attenuated
inversion recovery.
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Figure 9.
Tractography image demonstrates the
intimate relationship of right frontal mass with
the corticospinal tract (blue colored fibers).

Figure 11.
Pre- and immediate post-operative (at 24 hours) axial t1CE weighted images. On post-operative image, there is minimal residual enhancement particularly along the medial aspects of
the surgical site, concerning for minimal residual tumor. Majority of the hyperintense signal
in the right parieto-occipital region is related to blood post-operative blood products. T1CE,
T1-weighted contrast-enhanced.

MR imaging to define the at risk target
volumes and organs at risk.

Figure 10.
Dynamic susceptibility contrast (DSC)
perfusion weighted image. There is
increase in rCBV (relative cerebral blood
volume) in the region of right frontal
mass (Figures 1-4), a finding favoring high
grade neoplasm.
for adequate post-operative recovery.
Radiotherapy planning includes registration (aka “fusion”) of the post-operative
MRI (T1CE and FLAIR sequences) with the
planning simulation CT, which allows for
delineation of the FLAIR abnormality and
residual enhancement in treatment planning. Guidelines for these delineations
exist, but substantial variation is observed
among practitioners from different cooperative groups (e.g., RTOG22 vs. EORTC23),
and even among practitioners from one
country,24 but all utilize post-operative
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It is common to identify shifting of brain
parenchyma on planning CT in the weeks
after craniotomy as the normal brain
tissue expands to fill the space taken out
by the tumor. One study demonstrated a
4mm shift in the position of the treatment
isocenter between CT and MRI-based
target delineation,25 even with only a few
days between studies. The magnitude
of the shift can be several centimeters, resulting in inaccurate registration
between post-operative MRI and simulation CT. Many institutions have begun the
practice of obtaining repeat MRI at the
time of simulation to better characterize
the soft tissues for target delineation.
Advanced imaging at this time point may
play a role in radiation planning. A Polish
study demonstrated the discordance
between gross tumor volume (GTVs)
delineated from MRI as compared to
18F-fluoroethylthyrosine-PET (FET-PET), a
functional imaging modality; FET-PET was
better associated with the site of eventual
failure, suggesting that traditional target
volumes may not be adequate.26 ADC
maps generated from diffusion imaging
can identify areas of restricted diffusion
that may predict for areas of eventual
recurrence with high concordance;27,28

along with fractional anisotropy measurements from diffusion images, ADC values
may be associated with poor response to
treatment and worse survival among high
grade glioma patients.29 Diffusion and
perfusion parameters, when combined with
standard MR sequences, may allow radiation oncologists to better characterize the
highest-risk regions to include in high-dose
target volumes, utilizing macroscopically visible features30 as well as radiomic
features.31 Voxel-based MR spectroscopy
(MRS) and whole-brain spectroscopic MRI
(sMRI) may identify regions of tumor infiltration and areas at high risk of recurrence;32
regions with metabolic abnormalities on
sMRI are correlated with intraoperative
tissue samples showing increased immunohistochemical staining for neoplastic cells.33

Response Assessment
As demonstrated at any multidisciplinary
tumor board, imaging is of utmost importance in the interpretation of the response to
treatment in glioblastoma. The first widelyadopted set of guidelines for standardizing
the assessment of treatment response that
utilized MR imaging was the Macdonald
criteria,34 which used clinical parameters in
conjunction with imaging measurements to
classify responses into four broad categories (complete response, partial response,
stable disease, and progressive disease).
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Figure 15.
Immediate post-operative (at 24 hours) axial
post contrast T1 weighted image. There is
minimal residual peripheral enhancement
particularly along the medial aspects of the
surgical site concerning for small amount of
residual tumor.
Figure 12.
Single voxel MR spectroscopy at long TE (288 ms) acquired through the right temporoparietal
region mass with imaging appearance compatible with glial neoplasm. There is markedly
elevated choline (resonates at 3.2 ppm) with markedly decreased NAA (resonates at 2 ppm), a
finding consistent with high grade glial neoplasm. MR, magnetic resonance.

Figure 16.

Figure 13.

Figure 14.

Axial FLAIR and post contrast T1 weighted
images demonstrate a large heterogeneously enhancing mass in the right
parieto-occipital region with surrounding
FLAIR hyperintense signal, compatible
with high grade glial neoplasm. FLAIL,

Immediate post-operative
(at 24 hours) axial post contrast T1 weighted
image. There is minimal residual peripheral
enhancement particularly along the medial
aspects of the surgical site concerning for
small amount of residual tumor.

fluid-attenuated inversion recovery.
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Follow up of a case of glioblastoma on
therapy. Axial FLAIR weighted image demonstrates a large area of infiltrating hyperintense
signal abnormality in right temporo-occipital
region, with associated mass effect and leftwards shift of midline. FLAIR, fluid-attenuated
inversion recovery.
Challenges and limitations of the
Macdonald criteria became apparent
as imaging modalities revealed more
details about gliomas and their response
to treatment. The importance of noncontrast-enhancing regions of abnormality
has become better understood; for
example, changes in the volume of
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Figure 17.
Axial T1CE image depicts an area of
heterogeneous enhancement in right
temporal lobe within the region of FLAIR
signal abnormality. FLAIR, fluid-attenuated
inversion recovery. T1CE, T1-weighted
contrast-enhanced.

Figure 18.
Axial post-contrast T1 (T1CE) images at 8 months. There is a large heterogeneously enhancing
mass in the right parieto-occipital region at the operative site. There is interval development of
multiple enhancing nodules along the ependymal surface of ventricles, particularly along the
right frontal and temporal horn, and roof of fourth ventricles. These findings are compatible with
tumor progression. T1CE, T1-weighted contrast-enhanced.
is most commonly observed in patients
whose tumors harbored a methylated
MGMT promoter region,36 and makes
accurate assessment of response difficult,
especially in the setting of clinical trials
attempting to answer the question of efficacy of novel treatment regimens. Some
medications, including anti-angiogenic
drugs and immunologic agents, elicit
unique radiographic changes which may
mask accurate response assessment as well.

Figure 19.
On dynamic susceptibility contrast (DSC)
perfusion weighted imaging, the area
of signal abnormality predominantly
demonstrates low relative cerebral blood
volumes. The overall findings were consistent with pseudoprogression.
hyperintensity on post-treatment FLAIR
imaging, relative to baseline, are correlated
with improved survival.35 Furthermore,
some glioblastomas demonstrate imaging
changes consistent with progression under
the Macdonald criteria, but upon repeat
surgical intervention, viable tumor cannot
be identified in the resection specimen,
suggesting that the adjuvant treatment
may actually be having a positive effect that
eludes detection on conventional imaging.
This finding, termed “pseudoprogression,”
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These limitations, among others, led to the
development of a new set of guidelines
developed by the Response Assessment
in Neuro-Oncology (RANO) working
group,37 which incorporates more information from MR imaging, including FLAIR
sequence changes, into the objective
assessment. The RANO criteria have been
incorporated into clinical trials and daily
clinical practice, allowing better applesto-apples comparisons.38
Clinical trials in the last decade demonstrated the benefit of bevacizumab, an
anti-angiogenic monoclonal antibody, in
recurrent glioblastoma.39 The radiographic
appearance of malignant gliomas changes
dramatically after treatment with bevacizumab as a result of changes in vessel
permeability and contrast dynamics.40
Initial studies showed the difficulty in
distinguishing these radiographic changes
from true tumor effect; the temporal
dynamics were also unclear.41 These
issues led to the development of the

immunotherapy response assessment
in neuro-oncology (iRANO) criteria,42
which attempted to provide standardized
guidelines for the determination of tumor
progression in the setting of immunerelated therapy.
MRI imaging features have the potential to predict treatment response to
specific modalities of treatment. Relative
cerebral blood volume and dynamics
parameters (K¬trans and Ve), measured
by perfusion-weighted MR imaging and
other features may predict treatment
response to standard chemoradiation
and VEGF inhibitors,43-45 prior to initiation
of therapy. Radiomic features derived
from these images have been shown to
have predictive value as well.46

CONCLUSIONS
The volume of medical imaging data
continues to grow at an exponential rate. As
MR imaging becomes more cost-effective
and the adoption of advanced MR modalities becomes more widespread, it will
become more critical than ever to incorporate advanced imaging and the power
of large datasets into the management
of glioblastoma. We anticipate that these
changes will include not only the utilization
of new MR sequences but also novel image
analysis techniques, including radiomic
analysis, to better drive treatment decisionmaking, with the goal of improving clinical
outcomes in glioblastoma.
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Brain metastases are a significant cause
of morbidity and mortality among
oncologic patients, affecting 20-40%
of this population.1 Several therapeutic
strategies for intracranial metastases
exist, including stereotactic radiosurgery
(SRS), whole brain radiotherapy (WBRT),
surgical resection and supportive care
with steroids, though systemic therapy
remains an option for patients with
selected cancers.2 WBRT was historically
the treatment modality of choice for
brain metastases with or without surgical
resection.3,4 Technological improvements
in Gamma Knife and LINAC-based SRS
coupled with data indicating decreased
cognitive toxicity with SRS5, have led to
increased utilization of SRS6. Although
evidence-based clinical practice guidelines exist for the use of SRS for brain
metastases,7-12 there are comparatively
fewer reports that study specific aspects
of SRS plan evaluation or if current
use reflects the recommendations of
professional societies. In that context,
the current study represents one of the
few national surveys which specifically
investigates these issues to clarify the
role of SRS for intracranial metastases in
clinical practice.

Acknowledgements
E.S.B. received an F30 Ruth Kirschstein MD-PhD Fellowship Award (CA180500).

ABSTRACT
Background: Stereotactic radiosurgery (SRS) has emerged as an important modality for
the treatment of intracranial metastases. There are currently few established guidelines
delineating indications for SRS use and fewer still regarding plan evaluation in the treatment of multiple brain metastases.
Methods: An 18 question electronic survey was distributed to radiation oncologists
at National Cancer Institute (NCI) designated cancer centers in the US (60). Centers
without radiation oncologists were excluded. Physicians who indicated that they do
not prescribe SRS were excluded from the remaining survey questions. Sign test and
Chi-square test were used to determine if responses differed significantly from random
distribution.
Results: 116 of the 697 radiation oncologists surveyed completed the questionnaire,
representing 51 institutions. 62% reported treating patients with brain metastases using
SRS. Radiation oncologists prescribing SRS most commonly treat CNS (66.2%) and lung
(49.3%) malignancies. SRS was used more frequently for <10 brain metastases (73.7%;
p<.0001) and whole brain radiation therapy (WBRT) for >10 brain metastases (82.5%;
p<.0001). The maximum number of lesions physicians were willing to treat with SRS
without WBRT was 1-4 (40.4%) and 5-10 (42.4%) (p<.0001 compared to 11-15, 16-20
and no limit). The most important criteria for choosing SRS or WBRT were number of
lesions (p<.0001) and performance status (p=.016). The most common margin for SRS
was 0 mm (49.1%; p=.0021). The most common dose constraints other than critical
structure was conformity index (84.2%) and brain V12 (61.4%). The LINAC was the most
common treatment modality (54.4%) and mono-isocenter technique for multiple brain
metastases was commonly used (43.9%; p=.23). Most departments do not have a policy
for brain metastases treatment (64.9%; p=.024).
Conclusions: This is one of the first national surveys assessing the use of SRS for brain
metastases in clinical practice. These data highlight some clinical considerations for
physicians treating brain metastases with SRS.
Summary: This is among the first national surveys to assess the use of SRS for brain
metastases in clinical practice. Specifically, radiation oncologist reported increasingly
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using SRS instead of WBRT for treating
<10 metastases, with the LINAC being
the most common modality. Further,
treatment parameters considered the
most important included 0 mm margins,
conformity index, brain V12, and monoisocenter technique for multiple brain
metastases. These results may provide
context regarding the use of SRS for brain
metastases in clinical practice.
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MATERIALS AND METHODS
Study Design
An 18 question, non-incentivized electronic survey was distributed to radiation
oncologists at National Cancer Institute
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designated cancer centers in the United
States (60). Centers without radiation
oncologists were excluded. The total
number of physicians contacted was 697.
Physicians who reported not prescribing
SRS were not invited to complete
remaining survey questions. Per institutional policy, this study was IRB-exempt.

number of lesions (p<.0001), histology
(p=.0014), performance status (p=.016)
and location (p<.0001) as determined by
sign-test. Leptomeningeal disease was
statistically significant versus all other
choices as the predominant contraindication to prescribing SRS without WBRT
(93%; CI [83-98%]).

Statistical Analysis

Treatment Modality and Planning

Depending on type of question, 95%
confidence interval (estimate of proportion), sign test (difference from expected
mean) or Chi-square test (difference
from expected distribution) were used
to determine if responses differed
significantly from random distribution.
All data analyses were completed using
Stata software and a P value<0.05 was
considered to be statistically significant.

LINAC (54.4%) was more commonly
used than the CyberKnife (14.0%) or
Gamma Knife (31.6%) for SRS treatment (p=.0009). The mono-isocenter
technique for multiple brain metastases
was commonly used (43.9%; p=.23). The
most common margin for SRS was 0 mm
(49.1%; p=.0021), with 38.6% and 12.3%
prescribing a 1 mm and 2 mm margin,
respectively. The most common dose
constraints other than critical structure
were conformity index (84.2%) and V12
(61.4%). Diameter, volume and histology
of lesion were all ranked as significant
in determining the SRS prescription
dose (sign-test, p<.0001, p=.001 and
p<.0001, respectively). Notably, most
departments do not have a policy in
place for treating brain metastases with
SRS (64.9%; p=.024).

RESULTS
Response and Demographic Data
All survey results are reproduced in
Table 1. Of 697 physicians surveyed, 118
(16.9%) responded, with 28.7% reporting
that they do not treat brain metastases
with SRS. Respondents represented 51
different institutions across 28 states
with varying years of practice experience.

Indications and Use in Practice
Respondents primarily treated CNS (66.2%,
95% CI [54-77%]); lung was numerically
the second most commonly treated
disease site (49.3%). SRS (73.7%) was
used more frequently than WBRT (10.5%)
for <10 brain metastases (p<.0001) while
WBRT (82.5%) was used more frequently
than SRS (5.3%) for >=10 brain metastases (p<.0001). The maximum number
of lesions physicians were willing to treat
with SRS without WBRT in the treatment
session was 1-4 (40.4%) and 5-10 (42.4%)
(p<.0001; compared to 11-15, 16-20 and
no limit). Most physicians reported they
would not treat more than 10 lesions
over multiple sessions with SRS (43.9%;
p=.0003) but 19.3% reported there was
no limit to the number they would treat.
Physicians indicated that their practice
had changed in the past 5 years by more
frequently using SRS without WBRT
(84.2%) and SRS without other treatments
(i.e. surgery or WBRT; 82.5%). Criteria used
to determine SRS versus WBRT use were
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DISCUSSION
Despite increasing use of SRS to treat
brain metastases, little exists in terms
of guidance for physicians using this
modality. Moreover, our data indicate that
most departments do not have policies
governing SRS use. Importantly, no clear
guidelines exist regarding the maximum
number of metastases for which SRS is
recommended, despite a historicallyused cutoff of 4 in clinical trials.5,13,14 In
this study, 42.4% of respondents reported
using SRS for patients with 5-10 metastases and 17.5% of respondents offering
it for more than 10 lesions without WBRT.
Thus, a significant number of respondents
are using SRS for more than the standard
4 lesions. In total, 73.7% of respondents
reported using SRS more often for <10
metastasis, and 82.5% used WBRT more
often for >10 lesions. These physicians
may be influenced by a shifting paradigm
towards SRS alone for a greater than 5
or greater than 10 lesions.15-17 Indeed,
the majority of respondents reported
increasing their use of SRS over the last

five years. While the survey did not evaluate the role insurers play in physicians’
decision making, private insurance typically recognizes the role of SRS in treating
multiple brain metastases with no clear
maximum identified.18 Additionally, citing
a growing body of literature regarding
safety and efficacy, current National
Comprehensive Cancer Network (NCCN)
recommendations for SRS alone do not
specify a maximum number of lesions.19
Knisely et al first examined the use of
SRS in clinical practice several years ago;
physicians at two conferences hosted by
national stereotactic radiosurgery societies were asked to fill a questionnaire,
with a majority of respondents considering it “reasonable” to treat greater
than 5 metastases with SRS alone.20
More recently, Sandler et al evaluated practicing physicians’ “cutoff” for
treating brain metastases with SRS alone
versus WBRT, among other scenarios.21
Importantly, they found CNS-specialists
to be comfortable treating a mean of
8.1 lesions compared to 5.6 and 5.1
lesions for low-volume CNS specialists
and non-CNS specialists respectively.21
While our survey did not stratify SRS use
according to specialization, our results
reflect a similar trend among physicians
at a national level for treating greater than
five lesions with SRS alone.
Notably, recent American Society for
Therapeutic Radiology and Oncology
(ASTRO) Choosing Wisely guidelines
recommend against using adjuvant
WBRT with SRS, and instead recommend SRS monotherapy for brain
metastases.12,22 However, no guidance is
provided regarding the SRS plan evaluation. The present study identifies several
parameters in current SRS use for brain
metastasis in practice, including the use
of 0 mm margins, conformity index, brain
V12, and the mono-isocenter technique
for multiple brain metastases. While our
survey did not specifically assess the
values used for each parameter, retrospective data indicate that V12 greater
than 10.9 cm3 is associated with a 51%
1 year risk of radionecrosis.23 Likewise,
other treatment parameters appear to
play an important role in the development
of a safe and effective treatment plan.
The overall response rate was low for
this study, introducing the potential for
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response bias. Despite this potential
limitation, emerging research suggests
that low response rates are not inherently associated with inaccurate results
or nonresponder bias.24,25 Moreover, the
wide geographic spread and distribution
of practice experience among respondents suggests that the current sample
was representative of the academic field
at large. As this survey was distributed to
physicians practicing at NCI-designated
cancer centers however, the responses
may not be reflective of the patterns
of SRS use in private practice. Another
potential limitation of the survey was
that it did not account for patient volume
per institution, which may be a surrogate
for expertise in SRS and could influence
aggressiveness in treating multiple brain
metastases. Furthermore, individual
practitioners were not asked about their
patient volumes, which may be a surrogate for clinical versus research time in an
academic setting and therefore influence
management preferences. Future studies
will be needed to continue to address
these issues and refine clinical practice.

CONCLUSIONS
To our knowledge, this is among the first
national assessments of the use of SRS
for brain metastases in clinical practice
in the U.S. The data indicate that radiation oncologists are increasingly using
SRS for the treatment of intracranial
lesions, even in situations which were
historically treated with WBRT. Treatment
parameters considered most by respondents include 0 mm margins, conformity
index, brain V12, and a mono-isocenter
technique for multiple brain metastases.
These data may reveal areas that require
guidance and instruction from cooperative group committees.
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Let’s Talk About It
Jefferson’s Brain Tumor Support Group is the perfect
place for patients and their loved ones to talk about
living with a brain tumor. Jefferson staff members
are present and available to answer any questions
or concerns you may have.

Second Thursday of every month
6:30 PM to 7:30 PM
Jefferson Hospital for Neuroscience (JHN)
900 Walnut Street, 3rd Floor
Philadelphia, PA 19107
Free parking available at the JHN parking lot

If you have questions, please call

215-955-7000
RSVP is requested, but not required.

Published by Jefferson Digital Commons, 2018

JHN JOURNAL

43

39

JHN Journal, Vol. 13 [2018], Iss. 1, Art. 7

Dr. David Andrews is honored as the first
Anthony Alfred Chiurco Professor

The Jefferson family had a double celebration on July 19, 2017,
to thank Dr. and Mrs. Anthony Chiurco for establishing the
Anthony Alfred Chiurco, MD Professor in the Department of
Neurological Surgery, and to recognize the neurosurgical talents
of Dr. David Andrews, who was installed as the first Anthony
Alfred Chiurco Professor.
The celebration served as a reminder of how Jefferson improves
lives every day through philanthropic partnerships that establish initiatives such as the Vickie and Jack Farber Institute for
Neuroscience. The investiture was also a great opportunity to
acknowledge Dr. Chiurco’s Class of 1967, which is celebrating
its 50-year reunion this year.

This has led to the formation of a company to accelerate this
research, and his team has raised $14.8M in an initial round to
achieve this. He is recognized as a pioneer in radiosurgery and
established the first radiosurgery program in the Delaware Valley
in 1991. He designed a low-dose fractionated radiotherapy technique that restored vision in patients with optic nerve sheath
meningiomas. His landmark paper summarizing the results of a
phase III randomized trial demonstrating the benefit of radiosurgery in treating brain metastases was published in The Lancet in
2004. He has lectured throughout the world and has published
more than 120 peer-reviewed and invited papers.

ABOUT ANTHONY A. CHIURCO, MD
ABOUT DAVID W. ANDREWS, MD
As a neurosurgeon practicing neuro-oncologic neurosurgery
over a 28-year period, Dr. Andrews has vast experience in the
diagnosis, management and treatment of brain tumors. He
established the Brain Tumor Division in the Department of
Neurological Surgery at Thomas Jefferson University in 1995,
and as division chief has built a world-class group including
four neurosurgeons and two neuro-oncologists currently
performing more than 1,200 major cases a year. While training
as a resident at New York-Presbyterian/Weill Cornell Medicine
he also completed a one-year fellowship at Memorial SloanKettering Cancer Center.
As a junior attending surgeon, he was awarded a K11 Physician Scientist Award and studied the molecular pathogenesis
of malignant gliomas under Dr. Carlo Croce. Currently he is
the sponsor investigator and chief architect of a novel FDAapproved phase 1b immunotherapy trial for patients with newly
diagnosed glioblastoma, which is achieving remarkable results
in the highest vaccine cohort.
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Dr. Anthony A. Chiurco is recognized as one of the best diagnostic and clinical neurosurgeons in the country. For more than
30 years he served as chief of Neurosurgery at the University
Medical Center of Princeton and also served as chairman of
the Department of Surgery at Capital Health System (Fuld and
Mercer campuses).
Since 2002, Dr. Chiurco has been annually named among
America’s top surgeons by the Consumers Research Council
of America. He was attending neurosurgeon to the New Jersey
State Police, a spine surgeon for the U.S. Olympic rowing team,
and is a past president of the New Jersey Neurosurgical Society.
He has performed more than 6,000 major intracranial and
spinal operations, with particular attention to brain tumors,
cerebral aneurysms, spinal stenosis and herniated cervical and
lumbar discs.
Dr. Chiurco is a 1967 graduate of the Sidney Kimmel Medical
College.
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Selected Recent Neuro-Oncology
Publications
• Shi W, Blomain ES, Siglin J, Palmer JJ, Dan T, Wang Y,
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Experience. World Neurosurgery. 2017.
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Endocrinologic Outcomes for Endoscopic Endonasal
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• Alyemni D, Miller AF, Couto P, Athas D, Roberts AL, Rufail M,
Andrews DW, Strayer DS, Kenyon LC. Histopathologic identification of Trypanosoma cruzi (Chagas’) encephalitis in an
AIDS patient. Human Pathology: Case Reports. 2017.
• Hernández-Estrada RA, Kshettry VR, Vogel AN, Curtis MT,
Evans JJ. Cholesterol granulomas presenting as sellar
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Support Groups
Brain Aneurysm and AVM Support Group at Jefferson
The Brain Aneurysm and AVM (arteriovenous
malformation) Support Group provides
support for individuals, family members and
friends who have been affected by cerebral
aneurysms, subarachnoid hemorrhage and
AVMs. The purpose of the group is to gain and
share knowledge and understanding of these
vascular anomalies and the consequences of
these disease processes. The group provides
mutual support to its members by creating an
atmosphere that engenders active listening
and sincere and thoughtful speech within a
caring environment.

When

Third Wednesday of every month (September through June)

Time

6:30-8:30 p.m.

Place

900 Walnut Street, 3rd Floor, Conference Room
Philadelphia, PA 19107

Moderator/
Secretary
Jill Galvao
Parking	
Complimentary parking is provided in the parking garage
located in the JHN Building (Jefferson Hospital for
Neuroscience) on 9th Street (between Locust & Walnut)
Information For additional information please call: 215-503-1714

The Brain Tumor Support Group at Jefferson
The Delaware Valley Brain Tumor Support
Group at Jefferson provides an opportunity
for patients and their families to gain support
in obtaining their optimum level of wellbeing while coping with, and adjusting to
the diagnosis of brain tumor. Members are
encouraged to share their support strategies
so members can confront the challenges
that this disease process has imposed on
their lives. The strength gained from group
can be a source of comfort and hope for
whatever lies ahead.

When

Second Thursday of every month

Time

7-8:30 p.m.

Place 	Jefferson Hospital for Neuroscience,
3rd Floor conference room
900 Walnut Street Philadelphia, PA 19107
Facilitator

Joseph McBride, BSN, RN and Katelyn Salvatore, BSN, RN.
215-955-4429 or katlyn.salvatore@jefferson.edu

Parking	
Complimentary parking is available at the Jefferson Hospital for
Neuroscience parking lot.
Light refreshments and snacks will be served.

Neurosurgical Emergency Hotline
Jefferson Hospital for Neuroscience
Aneurysms • AVMs • Intracranial Bleeds
7 day • 24 hour coverage

1-866-200-4854
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UPCOMING JEFFERSON
NEUROSURGERY CME PROGRAMS
A

s a part of the Vickie and Jack Farber Institute for Neuroscience at Jefferson, the Department of Neurological
Surgery is one of the busiest academic neurosurgical programs in the country, offering state-of-the-art treatment to
patients with neurological diseases affecting the brain and spine, such as brain tumors, spinal disease, vascular brain
diseases, epilepsy, pain, Parkinson’s disease and many other neurological disorders (Jefferson.edu/Neurosurgery).
As part of a larger educational initiative from the Jefferson Department of Neurological Surgery, the Sidney
Kimmel Medical College Office of Continuing Medical Education is offering the following continuing professional
educational opportunities for 2018:

• 7th Annual Neurocritical Care Symposium
January 26-27, 2018
Jefferson Alumni Hall, Center City Campus of
Thomas Jefferson University

• 17th Annual Cerebrovascular Update
March 15-16, 2018
Hyatt at the Bellevue, Philadelphia

• Fundamental Critical Care Support Course
April 12-13, 2018
Dorrance H. Hamilton Building, Center City Campus of
Thomas Jefferson University

• 4th Annual Philadelphia Spine Summit
May 11, 2018
Jefferson Alumni Hall, Center City Campus of
Thomas Jefferson University

• 8th Annual Brain Tumor Symposium
October 2018
Philadelphia, PA

• 30th Annual Pan Philadelphia
Neurosurgery Conference
December 2018
Philadelphia, PA
For additional information regarding these and other Jefferson CME
programs, please visit our website at CME.Jefferson.edu or call the Office
of CME at 888-JEFF-CME (888-533-3263).
Sidney Kimmel Medical College at Thomas Jefferson University is
accredited by the ACCME to provide continuing medical education
for physicians.
Many of the activities above offer additional CE accreditations.

Follow us on Twitter at @JeffCME
for updates and new information
Published by Jefferson Digital Commons, 2018
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This is the frontier for neuroscience,
and we are its pioneers.

From the nation’s first brain surgery, to our dedicated center
for ALS research and patient care, Jefferson is at the forefront of
neuroscience discovery and disease treatment. We’re forging
ahead again – with the brightest minds in neuroscience, neurology,
neurosurgery and psychiatry – collaborating as never before within
one institute – the Vickie and Jack Farber Institute for Neuroscience.
More brainpower. More breakthroughs. Better outcomes – for you.
1-800-JEFF-NOW | Jefferson.edu/Farber

P H I L A D E L P H I A | M O N TG O M E RY CO U N T Y | B U C K S CO U N T Y | S O U T H J E R S E Y

https://jdc.jefferson.edu/jhnj/vol13/iss1/7
DOI: https://doi.org/10.29046/JHNJ.013.1

48

